Professional Documents
Culture Documents
A Dissertation
Presented to
The Academic Faculty
by
Hyun-Jung Lee
In Partial Fulfillment
of the requirements for the Degree
Doctor of Philosophy in the
School of Biomedical Engineering
1
DELIVERY OF THERMOSTABILIZED CHONDROTINASE ABC
ii
ACKNOWLEDGMENTS
First of all, I would like to acknowledge my advisor, Prof. Ravi V. Bellamkonda, for
his guidance over the years. He encouraged me to continue my research career, provided a
great environment, and always will be a good mentor. I feel lucky to have a chance to work
with him.
Bommarius, Prof. Andrés J. García, Prof. Niren Murthy and Prof. Robert J. McKeon. I am
all members of the Neurological Biomaterials and Cancer Therapeutics Laboratory. The
memories of the times we have shared will be in my mind forever and I will wish the best of
Shannon who always emotionally supported me, listen to me and were there for me
My parents and my brother always provide me unconditional love and any supports
and prayed for me every morning. I know they are always with me and in my mind wherever
I stay.
iii
TABLE OF CONTENTS
CHAPTER
INTRODUCTION………………………………………………………………………...1
1.1. STATEMENT OF PROBLEM ............................................................................ 1
iv
2.4 THERAPEUTIC STRATEGIES FOR CONTROLLED RELEASE OF
AGENTS BY DELIVERY CARRIERS ............................................................ 26
2.6 CONCLUSIONS................................................................................................ 32
v
3.2.9 ANALYSIS OF TEMPERATURE DEPENDENT CONFORMATION
OF CHABC ............................................................................................ 56
3.5 CONCLUSIONS................................................................................................ 69
vi
4.2.4 QUANTITATIVE ANALYSIS OF CSPG DIGESTION AND
ASTROCYTE RESPONSE ................................................................... 84
4.5 CONCLUSIONS................................................................................................ 95
vii
5.3.1 LEVELS OF CSPG DEPOSITION AFTER SUSTAINED DELIVERY
OF CHABC AT 6 WEEKS.................................................................. 109
6.2 EFFECTS OF CHABC ON NERVE TISSUE AND IMMUNE SYSTEM .... 132
6.6 RATE AND AMOUNT OF CSPG DEPOSITION IN VIVO AFTER SCI ..... 136
6.9 RESERENCES……………………………………….…………….………...141
viii
LIST OF TABLES
ix
LIST OF FIGURES
Figure 2.2. Schematic structure of various CSPGs and hyaluronan. Figure from
Gilbert et al., 2005. ..........................................................................................12
Figure 2.3. Ribbon drawing of chondroitinase ABC I (figure from (Huang et al.,
2003)); the N-terminal (green), middle catalytic (blue) and C-terminal
domain (yellow), from top to bottom...............................................................14
Figure 2.6 Schematic of PEGylated protein. The circles represent the water cloud
recruited by the ether-oxygen groups of the PEG polymer. Figure
from Veronese and Mero, 2008. ......................................................................24
Figure 3.1. Micrograph of lipid microtubes formed from DC8,9PC lipid in bright
field microscopy, scale bar is 50 µm. Figure from Meilander et al.,
2001..................................................................................................................52
Figure 3.3. SDS-PAGE assay for chABC enzymatic activity after 1 day pre-
incubation and 1 week of pre-incubation at 37 ºC with and without
trehalose. Lane 1: fresh chABC + decorin, Lane 2: 1 day pre-incubated
chABC + decorin, Lane 3: intact decorin, Lane 4: chABC, Lane 5: 1
week pre-incubated chABC + decorin, and Lane 6: 1 week pre-
incubated chABC with trehalose + decorin. Thermostability of chABC
was enhanced with trehalose and trehalose-chABC still retained the
ability to digest decorin after 1 week incubation at body temperature. ...........57
x
Figure 3.4. chABC enzymatic activity assay with different concentrations of
trehalose by SDS-PAGE. Each lane represents 1) 20 mM, 2) 50 mM,
3) 100 mM, 4) 250 mM, 5) 500 mM and 6) 1M of trehalose-chABC
with decorin after 2 weeks of pre-incubation at 37 ºC.....................................58
Figure 3.5. chABC enzymatic activity test after 4 weeks of pre-incubation with
and without trehalose at 37 ºC by SDS-PAGE. Lane 1: 4 weeks pre-
incubated chABC with trehalose + decorin, Lane 2: 4 weeks pre-
incubated chABC + decorin, Lane 3: fresh chABC + decorin, Lane 4:
decorin, Lane 5: fresh chABC + decorin, Lane 6: fresh P‟ase +
decorin, and Lane 7: fresh P‟ase (out of molecular weight range from
gel; ~28 kDa). The trehalose-thermostabilized chABC still retained its
activity to degrade CS-GAG of decorin after 4 weeks of pre-incubation
at body temperature and P‟ase had no effect on decorin CS-GAG. ................58
Figure 3.6. Kinetic analysis of chABC deactivation by DMMB assay. The X axis
represents days and the Y axis represents percentage of digested
decorin. Asterisks denote a significant difference from chABC in 1X
PBS (P < 0.05) and data represent mean ± SEM. The dotted line
represents the calculated deactivation curve of chABC in 1x PBS. Data
are mean ± SEM. chABC in 1X PBS (×) loses most activity within 5
days, and in contrast, chABC in 1 M trehalose (Δ) retains its activity to
degrade decorin CS-GAG up to 15 days..........................................................61
Figure 3.8. Enzymatic activity of post-released chABC from lipid microtubes. (A)
Quantification of the amount of CS-GAGs that remained after
digestion of decorin with the released enzymes by DMMB assay.
chABC (Δ) and P‟ase (×) with trehalose/microtubes. The Y-axis
represents percentage of digested decorin and the X-axis represents
time. All data points are significantly different (P < 0.05; mean ±
xi
SEM). (B) SDS-PAGE assay of chABC released from
trehalose/microtube + decorin..........................................................................64
Figure 4.1. Schematic of spinal cord injury model and delivery of enzyme to
lesion site. The 1 % SeaPrep agarose gel-microtube-scaffold is
implanted on top of the lesion and covered with stiffer 0.7% SeaKem
agarose gel to keep the scaffold in place. ........................................................80
Figure 4.2. Schematic of gel cooling system. Tubing runs from the nitrogen gas
tank to a Styrofoam box containing 100% ethanol and dry ice, and
runs through an aluminum rod inside a tube containing dry ice to keep
the nitrogen gas cool. The cooled nitrogen gas was applied over the
stiffer agarose gel solution for in situ gelation, which covers the top of
the gel-microtube delivery scaffold. Figure from Jain et al., 2006. .................80
Figure 4.3. This figure demonstrates the topical delivery model applied into the
spinal cord lesion site. A) Exposed intact spinal cord at T10 level after
a single laminectomy. B) Dorsal over hemisection injury made with a
single cut to the spinal cord column. C) Gel scaffold, embedded with
chABC loaded microtubes, implanted on top of the lesion site. D) The
implanted hydrogel-microtube delivery scaffold was covered with
stiffer agarose gel to stabilize its location on top of the lesion site. (R =
rostral, C = caudal) ...........................................................................................81
Figure 4.4. Micrographs of the GFAP immunostained tissue and method of image
analysis with a custom developed MATLAB program. A) 4x
immunostained image. The solid line represents the lesion boundary
defined by GFAP immunoreactivity and the boxed areas denote
regions selected for quantification. Scale bar is 500 µm. B) One of the
boxes in figure A is expanded at 20x magnification to show analysis of
fluorescent intensity using line profiles. The X axis represents distance
from the lesion interface in pixel unit. The lines were generated from
the lesion interface into the tissue, averaged and displayed as a
function of distance from the interface to between experimental
groups. Scale bar is 100 µm. ............................................................................85
xii
C) and MTC treatment (hydrogel-microtube delivery scaffold loaded
with chABC/ 1M trehalose; D, E, and F) animals. CS-56-IR for intact
CSPGs (A and D). 3B3-IR for digested CSPGs (B and E). WFA
staining for perineuronal nets (C and F). The intensity of CS-56-IR and
WFA is inversely proportional to 3B3-IR. Arrows in (C) indicate
WFA-PNNs. Scale bar is 100µm. ....................................................................88
Figure 5.1. CatWalk raw data in false color mode. White boxes represent
abnormal hindpaw print patterns. The dotted lines represent the stride
length defined as a distance between consecutive steps with the same
limb and the solid line represents the base of support defined as a
distance between the two hind paws. (dark red – left hindpaw, light red
xiii
– left forepaw, dark green – right hindpaw and light green – right
forepaw) .........................................................................................................106
Figure 5.2. Micrograph of CS-56-IR around the lesion site at 6 weeks. (A) MTCN
and (B) MTP. CSPG-IR is significantly less in the MTCN treated
animals compared to MTP treated controls. Scale bar is 100 µm. ................110
Figure 5.3. CatWalk raw data in false color mode, (A) Sham, (B) MTCN and (C)
MTP treated animals on the walkway at 6 weeks. All animal groups
show a normal step sequence. The white box in the figure C represents
an abnormal hindpaw print. Red represents left paw prints and green
represents right paw prints (dark red – left hindpaw, light red – left
forepaw, dark green – right hindpaw and light green – right forepaw). ........113
Figure 5.4. Stride length analysis for locomotion functional recovery. Data are
mean ± SEM and asterisk denotes statistical significance between
MTCN and MTP, and between MTCN and GC (P <0.05). Sham
showed significant differences († < 0.05) compared to all other
conditions throughout the testing period, except for MTCN at 4 and 6
weeks..............................................................................................................114
Figure 5.5. Micrographs of CTB labeled fibers (green) at the lesion site at 6
weeks. The dashed lines represent the lesion interface. (A) MTP and
(B) MTCN at 10 x magnification. Scale bar is 500 µm (C) An
expanded figure from the white box 0 to 0.5 mm interval in figure A,
and (D) an expanded figure from the white box in 0.5 to 1 mm interval
figure B at 20 x magnification. Arrows represent CTB labeled fibers.
Scale bar is 100 µm. .......................................................................................116
Figure 5.6. Quantification of CTB+ axon growth. The Y axis represents the
percentage of crossed axons at the distance to the lesion interface and
the X axis represents distance to the lesion (mm). The data represent
the mean ± SEM. Asterisks denote a significant difference compared
with MTCN (P<0.05). ....................................................................................117
xiv
Expanded figures from the white box in figure A. Serotonergic
innervations rostral to the lesion in MTP (B) and MTCN (C) animals
at 20× magnification. MTCN treated animal has higher fluorescent
intensity and also had extended closer to the lesion site than MTP
treated animal. Scare bar is 100 µm. ..............................................................119
Figure 5.8. Quantitative analysis of 5-HT-IR intensity for the stained spinal cord.
Quantification demonstrated that caudal to the lesion, MTCN showed
significantly (* p <0.05) increased 5-HT-IR compared to all other
treatments, and rostral to the lesion, MTCN showed significantly (* p
<0.05) increased 5-HT-IR compared to all other treatments except for
MTC. Data are mean ± SEM. ........................................................................120
xv
SUMMARY
Chondroitin sulfate proteoglycans (CSPGs) are one major class of axon growth
inhibitors that are upregulated and accumulated around the lesion site after spinal cord injury
of CSPGs with chondroitinase ABC (chABC) has been explored and it has shown promising
results. chABC digests glycosaminoglycan chains on CSPGs and can thereby enhance axonal
regeneration and promote functional recovery when delivered at the site of injury. However,
chABC has a crucial limitation; it is thermally unstable and loses its enzymatic activity
rapidly at 37 ºC. Therefore, it necessitates the use of repeated injections or local infusions
with a pump for days to weeks to provide fresh chABC to retain its enzymatic activity.
In this dissertation, three studies are reported that demonstrate our strategy to
overcome current limitations of using chABC and develop a delivery system for facilitating
chABC treatment after SCI: First, we enhanced the thermostability of chABC by adding
trehalose, a protein stabilizer, and developed a system for its sustained local delivery in vivo.
change of the enzyme was measured via circular dichroism (CD) with and without trehalose.
sustained release and showed that chABC released from the delivery system is still
functionally active and slowly released over 2 weeks in vitro. Second, the hydrogel-
xvi
microtube system was used to locally deliver chABC over two weeks at the lesion site
following a dorsal over hemisection injury at T10. The scaffold consisting of hydrogel and
chABC loaded lipid microtubes was implanted at the top of the lesion site immediately
animal groups treated with single injection or gel scaffold implantation of chABC and
penicillinase (P‟ase) were included as controls. Two weeks after surgery, the functionality of
released chABC and the cellular responses were examined by immunohistological analysis
with 3B3, CS-56, GFAP and Wisteria floribunda agglutinin (WFA). The results
demonstrated that thermostabilized chABC was successfully delivered slowly and locally
without the need for an indwelling catheter by using the hydrogel-microtube delivery system
in vivo. The results demonstrated that released chABC from the gel scaffold effectively
digested CSPGs, and therefore, there were significant differences in CSPG digestion at the
lesion site between groups treated with chABC loaded microtube-hydrogel scaffolds and
controls. Third, a long term in vivo study (45 days) was conducted to examine axonal
microtube loaded chABC or Neurotrophin-3 (NT-3), and a combination of them by using the
hydrogel-microtube delivery system. Over the long term study period, the treated animals
showed significant improvement in locomotor function and more sprouting of cholera toxin
B subunit (CTB)-positive ascending dorsal column fibers and 5-HT serotonergic fibers
facilitates the development of a minimally invasive method for sustained, local delivery of
chABC that is potentially a useful and effective approach for treating SCI. In addition to that,
xvii
we demonstrated that combinatorial therapy with chABC and neurotrophic factors could
provide a synergistic effect on axonal regrowth and functional recovery after SCI.
xviii
CHAPTER 1
INTRODUCTION
Unlike in the peripheral nervous system (PNS) or embryonic nervous system, in the
central nervous system (CNS) the severed axons fail to regrow through the lesion site, even
There are approximately 255,000 people living with SCI in the United States and
there are 12,000 new cases added each year. After injury to the central nervous system, the
lesioned axons fail to re-grow and recover function (Schwab and Bartholdi, 1996). The
extent of sensory and motor function loss after spinal cord injury (SCI) varies depending on
the level of injury, and often results in permanent functional loss. Complete neurological
recovery after SCI is experienced by less than 1% of patients. Since 2000, the most frequent
paraplegia (23.0%), complete tetraplegia (18.3%), and incomplete paraplegia (18.5%). The
cost for treatment is up to $ 0.7 million per patient in the first year, and the lifetime cost is up
to $ 3 million (National Spinal Cord Injury Statistical Center, 2008). The cellular and
molecular mechanisms of the inflammation process, cell death, the mechanism of axon
growth failure and receptor/targeting relationships are all active areas of research. While
1
A challenge in the environment of the injured spinal cord is that the inhibitory
molecules create a non-permissive environment for axonal regrowth and it results in a failure
of axonal regeneration and complete functional recovery. chABC, which digests CS-GAGs
on CSPGs, has shown promise as a therapeutic agent for SCI treatment (Yick et al., 2000;
Krekoski et al., 2001; Bradbury et al., 2002) and CNS regeneration (Moon et al., 2001; Fox
and Caterson, 2002; Pizzorusso et al., 2002). However there are crucial limitations and
difficulties to be applied for clinical treatment; chABC is thermally very unstable and it loses
its enzymatic activity quickly at body temperature. Therefore, multiple injection of chABC or
mini-pump/catheter-mediated delivery system has been used to provide fresh chABC in vivo
for long periods. However, these infusion systems are invasive and require much effort to
maintain. In this study, an alternative strategy for chABC delivery in vivo is developed and
tested alone or in combination with neurtophin-3 (NT-3) to enhance axonal regeneration after
SCI.
1.2. HYPOTHESIS
chondroitinase ABC will promote axonal regeneration and functional recovery after SCI. The
chABC digestion will remove the inhibitory effect of CSPGs limiting axonal regeneration
after CNS injury and provide a permissive substrate for axonal outgrowth. We hypothesized
that delivery of thermostabilized chABC using our slow and local delivery system will
provide a sufficient amount of bioactive chABC to effectively digest CSPGs at the lesion site.
Also, the delivery method will be more efficient than single injection of an equal amount of
chABC to digest CSPGs, and it will enhance axonal sprouting/regeneration and induce
2
behavioral recovery. Therefore, our slow local delivery system could be an alternative
method to current mini-pump/catheter delivery methods, which are invasive and infection-
prone because they are chronically implanted. We believe that a combination strategy of
chABC and neurtophin-3 using the slow release delivery system will encourage even more
Strategies to solve these challenges are: 1) protein stabilizers; 2) lipid microtube and
hydrogel mediated delivery system; and 3) a topical delivery model to the dorsal over
hemisection injury.
3
1.3. OBJECTIVES
The overall purpose of the work described in this thesis is to develop an approach to
for SCI, it is necessary to improve thermostability of chABC and develop a delivery strategy
1. To improve the thermal stability of chABC and develop a minimally invasive and
delivery system with a topical delivery model and examine the functionality of
after implantation.
effects and examine axonal sprouting/regeneration and functional recovery after SCI.
4
1.4. REFERENCES
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon
SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury.
Nature 416:636-640.
Fox K, Caterson B (2002) Neuroscience. Freeing the brain from the perineuronal net. Science
298:1187-1189.
Krekoski CA, Neubauer D, Zuo J, Muir D (2001) Axonal regeneration into acellular nerve
grafts is enhanced by degradation of chondroitin sulfate proteoglycan. J Neurosci
21:6206-6213.
Moon LD, Asher RA, Rhodes KE, Fawcett JW (2001) Regeneration of CNS axons back to
their target following treatment of adult rat brain with chondroitinase ABC. Nat
Neurosci 4:465-466.
Schwab ME, Bartholdi D (1996) Degeneration and regeneration of axons in the lesioned
spinal cord. Physiol Rev 76:319-370.
Yick LW, Wu W, So KF, Yip HK, Shum DK (2000) Chondroitinase ABC promotes axonal
regeneration of Clarke's neurons after spinal cord injury. Neuroreport 11:1063-1067.
5
CHAPTER 2
RELEVANT BACKGROUND
Injuries trigger cellular and molecular signal cascades which upregulate inhibitors to
axonal outgrowth and result in regenerative failure. Inhibition could be caused by myelin-
(ECM) molecules, and the lack of trophic factors. One major class of growth inhibitors are
chondroitin sulfate proteoglycans (CSPGs) that accumulate around lesion site after SCI.
when delivered into lesion sites. However, chABC loses its enzymatic activity rapidly at 37
ºC, necessitating the use of repeated injections or local infusions with a catheter and pump
for days to weeks to digest the CSPGs being produced continuously. Maintaining these
To overcome the limitations of chABC therapy for clinical application, the following
technical achievements must be met; stable bioactivity of chABC, a delivery system for
limitations that need to be overcome are described, and alternative methods and strategies to
6
2.1 CELLULAR AND MOLECULAR RESPONSES AFTER SCI
After injury to the central nervous system (CNS), the inflammation process is
triggered, a series of cellular and molecular responses are cascaded and eventually glial scars
are formed around the lesioned tissue (Fawcett and Asher, 1999). The failure of neurite
regrowth and permanent functional loss result from these cellular events. To begin,
migrate into the lesion site. These cells produce inhibitory molecules, such as myelin-
associated glycoprotein (MAG), CSPGs and other proteoglycans, free radicals, nitric oxide,
etc. The final form is a tightly interwoven glial scar formed around the lesioned site (Rudge
and Silver, 1990). Macrophages from the bloodstream and microglia from the surrounding
tissues are the first cells to arrive at the site, usually within a few hours after injury. They
remove myelin debris, produce and release cytokines, recruit oligodendrocyte precursors and
initiate reactive astrocytes. Inhibitory molecules are up-regulated and the injury site is
precursors migrate from the surrounding tissue after 3-5 days and myelin debris contains
collapses the neuronal growth cone (Bandtlow et al., 1993); MAG is produced by and present
in oligodendrocytes (Kastin and Pan, 2005); and OMgp is most recently identified and
7
If meningeal layers, which cover the CNS, are penetrated, meningeal cells migrate to
cover the exposed area of CNS and form a barrier to axon regeneration. Astrocytes are the
predominant and final structure of the astro-glial scar with ECM and ECM molecules. These
cells divide in reactive form, slowly migrate into the injured area, fill the space caused by
injury, and produce inhibitory molecules, such as chondroitin sulfate proteoglycans (CSPGs).
This astro-glial scar acts as a barrier that prevents axons from passing through and inhibits
axonal regeneration. CSPGs are over-expressed in extracellular matrix at the lesion site
where reactive astrocytes are present, and ultimately form astro-glial scars that act as barriers
to axonal outgrowth. CSPGs are generally accepted as potent inhibitory molecules of axon
growth in the adult CNS. Therefore, recent studies focus on alleviating CSPG-mediated
inhibition by delivering the enzyme chABC in vivo and to encourage axonal regeneration and
functional recovery (Moon et al., 2001; Bradbury et al., 2002; Barritt et al., 2006).
It is known that axons of the CNS cannot regenerate to form functional connections
after injuries. However in the mid-1980s studies demonstrated that CNS neurons can
regenerate their axons over long distances when a favorable environment is provided (So and
studies suggest that attenuating inhibitory effects of CSPG by chABC digestion enhances
axonal growth and functional recovery. chABC is a bacterial lyase produced from the
bactreum Proteus vulgaris that is able to digest CSPGs. The therapeutic significance of
chABC has been demonstrated in studies that delivered this enzyme to enhance nerve
8
regeneration (Bradbury et al., 2002; Barritt et al., 2006). However there are several
CSPGs consist of a core protein and glycosaminoglycan (GAG) chain that are
covalently linked to form a brush-like structure (Fig. 2.1). The GAGs are linked to the core
protein by a trisaccharide composed of two galactose and one xylose residue. GAG is made
of repeating disaccharides containing either two modifier sugars, glucuronic acid (GlcNAc)
sugars can have over 100 individual sugar molecules and each can be sulfated in various
positions and quantities. Figure 2.2 shows that chondroitin sulfate glycosaminoglycans
CSPGs are upregulated after injury in the CNS and become a major contributor to the
failure of axonal regeneration (Pindzola et al., 1993; McKeon et al., 1995; Fitch and Silver,
1997; Asher et al., 2000; Asher et al., 2002; Jones et al., 2003; Tang et al., 2003). CSPGs
perineuronal nets (PNNs) (Matthews et al., 2002) in the brain and spinal cord, the roof plate,
a putative axon barrier, of the spinal cord and optic tectum (Snow et al., 1990a), and the
hippocampus (Wilson and Snow, 2000). Studies have shown that neurite outgrowth is
inhibited by CSPGs in vitro (Snow et al., 1990b; McKeon et al., 1991; Snow and Letourneau,
1992; Condic et al., 1999; Hynds and Snow, 1999; Snow et al., 2001; Johnson et al., 2002)
9
and in vivo after injury of optic nerve (Selles-Navarro et al., 2001) or the dorsal root entry
zone (Zhang et al., 2001). However, the precise contribution of different CSPGs to CSPG-
mediated inhibition in the CNS and the mechanism of cellular transduction of the inhibitory
signal mediated by CSPGs are not clear. Because CSPGs have a significant structural
diversity, the nature and profile of CSPG deposition patterns have been recently investigated
(Jones et al., 2003; Properzi et al., 2005). Specific CSPGs are differentially over-expressed in
astro-glial scar after injury and CSPGs have varying degrees of inhibition (Gilbert et al.,
2005).
After spinal cord injury, glial scars present a physical barrier and also produce
Letourneau, 1992; Zuo et al., 1998; Krekoski et al., 2001). Therefore, enhanced axonal
regeneration can be achieved by removing CSPGs or the GAG side chains of CSPGs with
chABC is one of a class chondroitinases and has a molecular weight of 120 to 145
bacterium Proteus vulgarism and there is no mammalian equivalent (Ryan MJ, 1994).
into disaccharides and tetrasaccharides, yielding protein enriched core molecules with a
10
Figure 2.1. Structure of chondroitin sulfate proteoglycan (CSPG). (A) versican,
a large CSPG belonging to the lectican family and (B) decorin, a small CSPG
of extracellular matrix.
(Figure modified from http://web.virginia.edu/Heidi/chapter9/chp9.htm)
11
Figure 2.2. Schematic structure of various CSPGs and hyaluronan. Figure
from Gilbert et al., 2005.
The chABC is isolated from Proteus vulgaris contain two distinct eliminases, endolytic
(chABC I) and exolytic (chABC II) lyases (Hamai et al., 1997). chABC is commercially
available and the commonly used chondroitinase enzymes are provided by Seikagaku
ABC, protease-free (chABC I)”. Usually the highly purified chABC, “chondroitinase ABC,
protease-free”, has been used for in vivo study and is used in this study.
chABC I is a 997 amino acid residue monomeric protein that degrades its substrates
to tetrasaccharides and disaccharides. The complete crystal structure of chABC I has been
12
determined to contain three domains: the N terminal, central, and C terminal domains. The
overall dimensions of chABC I is 115 Å × 70 Å × 55 Å and is folded into the three distinct
domains (Huang et al., 2003). This structure shows overall similarity to other GAG lyases
with additional domains on the N terminal. About 400 amino acid residues are in the C
terminal domain also shows a homology to chondroitinase AC (cAC; two domain) (Fethiere
et al., 1999) and bacterial hyaluronidases (Li et al., 2000). The role of this C-domain is not
clear, however, one loop in this domain acts as a substrate-binding site. The N terminal
domain consists of residues 25-234 and is the most flexible in chABC I compared to others.
The N-domain has a common topology to other ligand-binding domains, particularly the
carbohydrate-binding domains of xylanases and glucanases (Lo Conte et al., 2000). The
central domain (residues 235-617) contains 15 α-helices and is most likely the catalytic site.
The α-helix domain shows very similar sequence identity to the catalytic domains of cAC
and hyaluronidase. The active site of chABC I, as informed by superimposition with cAC
structure, has been investigated (Prabhakar et al., 2005a; Prabhakar et al., 2005b). However,
the active site has not been clearly defined and it is still unknown as to why chABC quickly
loses its enzymatic function at body temperature. In addition, a strategy has not been
13
Figure 2.3. Ribbon drawing of chondroitinase ABC I (figure from
(Huang et al., 2003)); the N-terminal (green), middle catalytic (blue)
and C-terminal domain (yellow), from top to bottom.
14
chABC has the widest substrate specificity; therefore, it has been used widely,
including as a therapeutic agent for SCI. Treatment with chABC has shown promising results
with various CNS applications, such as regeneration of ascending sensory neurons and
descending corticospinal tract axons in the spinal cord (Bradbury et al., 2002), sensory
neurons in the dorsal root entry zone (Steinmetz et al., 2005), and retinal ganglian cell axons
in the tectum (Tropea et al., 2003). Therefore, chABC offers a potential treatment strategy for
neural injury.
AND LIMITATIONS
chABC promotes axonal regeneration and functional recovery after CNS injury (Yick
et al., 2000; Moon et al., 2001; Bradbury et al., 2002; Yick et al., 2003; Chau et al., 2004)
and developmental disease (Pizzorusso et al., 2006). It promotes neurite sprouting in intact
and injured spinal cords (Barritt et al., 2006). Most groups deliver chABC via intrathecal
injection varying the infusion frequency from every other day to every other week, for time
periods ranging from 2 weeks up to 6 weeks (Chau et al., 2004; Caggiano et al., 2005; Houle
et al., 2006; Huang et al., 2006). Some groups inject chABC in combination with other
therapeutic agents (Tropea et al., 2003) or with transplantation, such as that of E14 fetal
spinal cords (Kim et al., 2006) or autologous peripheral nervous grafts (Houle et al., 2006), to
However, there are several limitations and difficulties to these methods. chABC is
quickly loses 50% of its enzymatic activity (by Morgan-Elson reaction). It loses most of its
15
enzymatic function after a day. In addition, CSPGs are upregulated and accumulate in the
extracellular matrix around the injured site up to at least 2 weeks after the primary injury.
chABC. Most of these deliveries are performed intrathecally with a catheter, so it is hard for
chABC to diffuse into deep regions of the tissue. Because intrathecal delivery allows the
drug to flow through intrathecal space, the drug washes away quickly and does not last a long
time in the target area. Also, because of this drug diffusion, the concentration immediately
are needed to compensate. This is a problem for chABC. Because this enzyme is very
are several problems to overcome; specifically there is a compelling need to control chABC
PROTEINS
industry. Since chemical reactions are generally faster at higher temperatures, enzymes,
which are stable at higher temperature, would yield a more efficient process (Schoemaker et
al., 2003; Unsworth et al., 2007). Also in the laboratory, thermally stable proteins/enzymes
are easier to store or handle. Many studies have been conducted to engineer thermostability
of proteins and there are two general strategies for protein engineering to improve the
thermal stability of proteins or enzymes (Bae et al., 2008): rational design and directed
16
evolution. Another strategy is to add cosolvents for modifying solvent environment (Cleland
In rational design, precise changes on amino acid sequence are designed from
detailed knowledge of the structure and function of the protein by using site-directed
mutation (Chen, 1999; Eijsink et al., 2004). It is generally inexpensive and easy, however the
detailed structure of a protein is often not available and even with the detailed information it
is difficult to predict the effect of mutation on protein functions. The other strategy, directed
evolution, involves generation of random mutations in the protein sequence, and does not
require information as to how the structure is related to function (Kuchner and Arnold, 1997;
Eijsink et al., 2005). This mimics natural evolution; random mutation is applied to a protein,
selected to pick desirable variants, and further rounds of mutation and selection are applied.
This directed evolution approach is hard to predict the results of stability and functionality,
stable variant. Many mutations that result in the most stable variant would have been difficult
to predict by rational design and the results of directed evolution are often better than rational
results. However these two techniques are not mutually exclusive and recently researchers
engineer proteins in combination of these methods to render desired changes (Eijsink et al.,
2004).
combination. Surface position is good candidate for optimizing protein stability (Martin et al.,
17
2002). Surface or near-surface interactions are important for protein stability. However, very
limited number of mutants can lead to an increase of stability and do not affect functionality.
Random method has been used to generate mutation and it can lead high stability, but some
of which are not easy to define rationally. Therefore, recently semi-rational method is
frequently used. To apply for our case, chABC, several charged residues could be selected
from the surface of the 3D structure (Prabhakar et al., 2005a; Prabhakar et al., 2005b), except
active residues, and randomly mutate these residues and find optimized mutants. The stability
crystal structure), and the functionality by enzymatic activity assays, such as, SDS-PAGE,
can be broadly categorized into the following: sugars and polyols (sugar alcohol), amino acid,
amines, salts, polymers and surfactants. The level of stabilization by different cosolvents
varies for particular proteins. Therefore, a cosolvent that stabilizes one protein/enzyme may
not stabilize another (Hatti-Kaul and Mattiasson). Sugars (Carninci et al., 1998) and polyols
(Xie and Timasheff, 1997a) are the more commonly used nonspecific protein stabilizers.
Amino acids are also commonly used as stabilizer or osmolytes (Taneja and Ahmad, 1994;
Remmele et al., 1998). The cosolvent may affect both the structural stability and activity of
protein. Sugars and polyols always have been shown to enhance the thermal stability of
proteins, but some amino acids have been found to destabilize the protein. The effects of salts
also depend on pH of the medium and their chemical nature (Rishi et al., 1998). Therefore,
18
sugar or polyol are safe candidates as cosolvents. Often higher concentration of protein
increases its own stability, however high concentration could lead a chance of protein
adsorption, however the concentration of surfactants need to be carefully decide to avoid side
stability of protein (Kaushik and Bhat, 2003). Trehalose accumulates dramatically during
heat shock and stationary phase in many organisms, then enhances thermo-tolerance and
stabilizer for chABC. It has not been found in mammals, however this improves the tolerance
during dehydration and desiccation (Sampedro et al., 1998). It promotes survival under
extreme heat by stabilizing proteins in order to retain their conformation and suppresses the
aggregation of denatured proteins (Singer and Lindquist, 1998). Further, trehalose stabilizes
labile proteins during lyophilization (Zhang et al., 2009), protects enzymatic activity, such as
19
with RNase A, lysozyme, cytochromes during exposure to high temperatures in solution, and
CHABC
protect biological materials under extreme conditions (Cottone et al., 2005; Hedoux et al.,
2006). Many studies have been conducted to understand the mechanism of trehalose and
possible mechanisms have been proposed, however the molecular mechanism of trehalose
stabilization is poorly understood (Hedoux et al., 2009). There are several hypotheses to
explain the mechanism of trehalose efficiency: 1) water replacement model (Crowe et al.,
of solutions (Green et al., 1989) and 4) the influence on the water tetrahedral hydrogen-bond
network (Branca et al., 1999). However, the molecular mechanism probably depends on the
20
The preferential interaction theory was proposed by Arakawa and Timasheff in 1983.
They observed that bovine serum albumin and lysozyme were preferentially hydrated in
amino acids. Preferential interaction is also stated as preferential binding of the cosolvent or
by the protein is the driving force of preferential interaction, which causes change of the
amount of water in contact with protein (Timasheff, 2002). Studies showed that trehalose
stabilizes the folded structure of proteins in solution due to greater preferential hydration of
the unfolded state compared to the native state (Xie and Timasheff, 1997b). Therefore, the
mechanism seems to be opposite from the stabilization mechanism in the dried state, which is
water replacement. Sugars generally protect proteins from dehydration by preventing the
decrease of spacing through hydrogen bonding to the dried protein surface, serving as a water
substitute (Carpenter et al., 1993). Like this, the mechanism of stabilization can be different
The primary mechanism by which trehalose is likely to affect the stability of the
proteins is by increasing the surface tension of water around the proteins due to hydrogen
bond formation between the hydroxyl groups of trehalose and water. In solution, trehalose
stabilizes RNase A by increasing the surface tension of the trehalose solution, leading to the
preferential hydration of the protein (Xie and Timasheff, 1997a). Surface tension of trehalose
solutions increases linearly with increasing trehalose concentration (Kita et al., 1994), and
there is a strong correlation between surface tension and increase in Tm (Jai et al., 2003).
Increasing solvent surface tension necessitates more energy to form a cavity in order to
increase the surface area of proteins upon denaturation. In fact, other protein stabilizers, such
as polyols and carboxylic salts (Kaushik and Bhat, 1999) show a correlation between surface
21
tension increase and enhanced protein thermal stability. Studies also have shown that the
dynamic fluctuation of polar side chains at the solvent-protein interface is reduced in the
presence of trehalose (Hedoux et al., 2009). The increased surface tension or the limited
polymerization of ethylene oxide with water, ethylene glycol or ethylene glycol oligomers
and various molecular weights of PEG can be prepared by modulation of the polymerization
(Abuchowski et al., 1977). In the study, methoxypolyethylene glycol was covalently attached
to bovine serum albumin and it lost its immunogenicity and the potential of PEG conjugation.
After this successful study, a number of studies followed and PEG has been applied to
several biological therapies and success have been achieved in parallel with improvements of
the PEG properties (Veronese and Mero, 2008). PEG is a biologically favorable molecule, a
non-toxic and non-immunogenic molecules approved by the US FDA for internal use.
PEGylation has been well established in the clinic and there are many PEGylated
Doxil/Caelyx (PEGylated liposome containing doxorubicin), etc (Veronese and Mero, 2008).
22
Figure 2.5 Poly(ethylene glycol)
PEGylation is can be applied to these therapeutic agents to modify or improve their stability,
attached PEG chains change the physical and chemical properties of the agents. Several PEG
chains are attached on the surface of agents and result in increasing the molecular weight and
creating water cloud surrounding the PEGylated agents by hydrogen bond formation between
shielding the PEGylated agents from the host‟s immune system reduces immunogenicity and
antigenicity and increases stability. It also provides high solubility in both aqueous and
organic solvent, high mobility in solution, high hydration increasing hydrodynamic size in
solution, and increases of the retention time in blood (Israelachvili, 1997). Due to the
fragments have been PEGylated for several drug delivery applications (Harris and Chess,
2003).
23
Figure 2.6 Schematic of PEGylated protein. The circles represent the
water cloud recruited by the ether-oxygen groups of the PEG polymer.
Figure from Veronese and Mero, 2008.
Hydroxyl group of the PEG terminal can react with the various protein amino acid
residues. Since amino groups are present in every protein, generally at the surface and
exposed to the solvent, it is the most exploited residue for PEGylation by alkylation or
acylation. Amino group modification can negatively affect surface properties of the protein
and in some cases the modification decreases enzymatic/biological activity (Banci et al.,
1990; Greenwald et al., 2003). Modifying cysteine thiol residue by formation of thio-ethers
catalysis or disulfide bridges, so available free cysteine residues are rarely present. Therefore,
hydrolysis, or linker self-immolation cleaves the link and releases PEGylation, regenerating
native agents and preserving its bioactivity. Recent reports demonstrate that the customized
linkers of cytokines, peptide hormones, enzymes or receptor proteins are released under
24
physiological conditions and at specific and therapeutically useful rates (Filpula and Zhao,
2008).
Other amino acid residues, such as arginine (Veronese and Mero, 2008), glutamine,
the alcohol group of serine and threonine, and the phenolic group of tyrosine (Orsatti and
Veronese, 1999) are usable sites for PEG conjugation. For glutamine residue conjugation, the
enzyme, transglutaminase, is used because there is no chemical method (Sato et al., 1996)
and this glutamine-PEGylation is very specific (Fontana et al., 2008). However, because of a
lack of specificity (arginine) and harsh reaction conditions (serine and theronine) other
Since covalent binding is involved in PEGylation, and several PEG chains are usually
linked on the surface, the size and conformation of the agents are changed. Also, there is a
possibility that conjugated PEG polymers can block the binding sites and active sites
resulting in loss or damage of the agent‟s bioactivity. Therefore, the mass, number of chains
and link positions need to be investigated for each case to maintain its bioactivity. To avoid
these complications, genetically engineered proteins can be used: a genetic variant of amino
acids is inserted at a site far from biologically active site and used for a residue to PEG
stabilizer. In our case with chABC, it would not be an ideal method for several reasons.
Linked PEG chains can mask catalytic site of chABC, however exact positions of the site are
still not clear and the mechanism of deactivation of chABC enzymatic activity is also
unknown. Therefore, it is not easy to design a relevant PEG polymer conjugation for chABC
25
and the increased size of chABC with PEGylation will result in limited diffusion through the
DELIVERY CARRIERS
drug delivery systems is widely investigated due to the increased needs as therapeutics.
Various carriers have been used for the efficient delivery of agents for different therapeutic
purposes. For slow and local delivery of chABC after SCI, it is important to control
temporally and spatially the amount of protein delivered over a period of time. Also, the
delivery vehicle is able to maintain bioactivity of the agents over the period of time. The
implanted vehicle itself and by-product of degraded vehicle should not induce significantly
delivery method of chABC for clinical and in vivo application to treat SCI is intrathecal
injection through the implanted catheter with mini-pump or syringe (Bradbury et al., 2002;
Barritt et al., 2006). This delivery system consists of two parts: 1) an infusion pump or an
external catheter end implanted under the skin on the back of the animal, and 2) catheter
inserted in the lesion site. However the internal catheter end is chronically implanted, and
human cases have reported that intrathecal catheter-tip causes inflammatory mass (Peng and
Massicotte, 2004), and surgical site infection (Burgher et al., 2007). Also an insoluble gelatin
sponge and gelfoam containing chABC was used to treat SCI (Yick et al., 2003). In this
26
2.4.1 POLYMER NANOPARTICLE
Various delivery vehicles are used to deliver drugs into the CNS and PNS, such as
liposomes, polymer nanoparticles and lipid microtubules. In order to locally deliver drugs for
spinal cord treatment, PLGA nanoparticles and lipid microtubules could be considered for
sustained delivery. Our laboratory has used both vehicles for in vivo sustained drug delivery.
PLGA is a biocompatible and biodegradable polymer and is approved by US Food and Drug
Administration for human use. PLGA nanoparticle have been used for sustain release of
encapsulated agents (Shive and Anderson, 1997). The double emulsion method is used to
make PLGA nanoparticles and is simple and takes a relatively short time, a total of 3 days.
However during the double emulsion procedure, the releasing agent, such as protein, can be
exposed to organic solvents (ex. Dichloromethane) and high temperatures. Without co-
limit in this paper) (Li et al., 2005). Therefore proteins undergo physical denaturation and
chemical degradation during fabrication (Sah et al., 1999; Kim et al., 1999) and
unpredictable release profiles often occur, such as a burst effect or incomplete release (Kim
et al., 1999). Only a few proteins have shown the ability of controlled delivery from PLGA
Lipid microtubes are also capable of the slow release of protein or bio-agents for in
vivo application. It spontaneously forms hollow and open-ended cylinders (Schnur, 1993)
with 0.5 µm of the average inner diameter and the lengths of the cylinders depend on the
27
cooling rate (Thomas et al., 1995; Meilander et al., 2001). Microtubes have a high aspect
ratio and it allows for a large storage volume and they are stable in physiological medium at
37 ºC (Spargo et al., 1995) for prolonged a period of time. The fabrication process takes a
relatively long time, a total of 15 days, and microtubes need to be prepared freshly. However,
there is no toxic procedure for proteins, which could cause denaturation or degradation,
during the fabrication process. Microtubes show a stable and continuous release profile and
could be used as sustained delivery vehicles for proteins, such as neurotrophic factors (Jain et
al., 2006), and even nucleic acids (Meilander et al., 2003). It is also easy to combine with
hydrogels to support a scaffold for in vivo application and non-inflammatory (Rudolph et al.,
1992; Meilander et al., 2001). Lipid microtubes are injectable either by themselves, or when
The study showed that an agarose hydrogel scaffold embedded by BDNF loading lipid
microtubes was implanted into a spinal cord cavity and led to the reduction of the
The molecules are released through the ends of microtubes, and a mathematical
model of release profile of proteins has been developed previously in our laboratory
(Meilander et al., 2004). The release of proteins can be predicted with the molecular weight
and protein concentration. The slow release of agents can be modified by controlling the
length of microtube, type of gel, and gel concentration for desire delivered amount of agent
28
2.5 PHARMACOLOGICAL STRATEGIES FOR SCI
There are limited therapies for SCI and no effective treatment to reduce damage and
which is a synthetic cortico-steroid and typically used for anti-inflammatory effect, has been
used as a drug for acute SCI in humans for three decades with limited clinical support, and it
is the only available drug for acute SCI in human. However it is based in large part on
physiological hypotheses and its beneficial effect on the neurological recovery of patients has
not been clearly proven (Hugenholtz, 2003). The effect of MP administration in patients with
acute spinal cord injury was clinically examined by National Acute Spinal Cord Injury Study
I, II and III (NASCIS) (Bracken et al., 1984; Bracken et al., 1985; Bracken et al., 1990;
Bracken et al., 1992; Bracken et al., 1997; Bracken et al., 1998). In NASCIS II, a patient sub-
group received a 24 hour high-dose infusion of MP within 8 hours following acute SCI
showed improved neurological recovery (Bracken et al., 1990). Therefore within 8 hours
after injury and high-dose infusion (typically 30 mg/kg bolus injection and 5.4 mg/kg/h
following injection over 23 hours) has been an implied standard for clinical treatment. The
high-dose of MP causes several side effects, such as impaired lung capacity and the higher
incidence of sepsis and pneumonia. Compelling evidence of its efficacy is not yet conclusive
(Gerndt et al., 1997). To minimize the side effects related to systemic delivery, localized
delivery methods have been developed: previously, our group developed a sustained and
local delivery method. MP was delivered on the top of the lesion site by agarose hydrogel
delivery system embedded with biodegradable polymer nanoparticles and showed effective
diffusion through the spinal nerve tissue and significantly reduced early inflammation
29
(Chvatal et al., 2008; Kim et al., 2009). However, still there is the confusion with MP utility
for acute SCI and MP should be used with caution, particularly if infusion goes longer than
24 hours.
A wide range of other pharmacological treatments have also been evaluated and in
some cases have shown potential with promising results. Cyclooxygenase (COX) is an
anti-inflammatory agent reducing inflammation and pain, and some selective (indomethacin;
(Pantovic et al., 2005)) or non-selective (NS-398 to COX-2; (Hains et al., 2001)) COX
isomerases and some IPs are receptor for immunosuppressive drugs such as cyclosporine A
and FK506 (Sosa et al., 2005). Drugs inhibits the activity of calcineurin, which is a protein
phosphatase and activates the T cells of the immune system, and the drug binding can
promote neuroprotective effect and results in inducing neuroregeneration (Ibarra and Diaz-
Ruiz, 2006).
acute CNS injury. Therefore, several therapeutic strategies have been applied to diminish its
effects (Hall et al., 1992). As previously mentioned, MP has been used for human SCI and
lazaroids, 21-aminosteroids, also show significant antioxidant effects without the same side
effects of MP (Hall and Springer, 2004). Tirilazad, one of lazaroids, was also examined in
the NACIS III and tirilazad treated patients showed slightly better neurological recovery, but
not significantly higher than those treated with MP (Bracken et al., 1997). Therefore, there is
30
Calpains are a family of calcium-dependent, non-lysosomal cysteine proteases.
Hyperactivation of calpains follows traumatic brain injury or spinal cord injury due to Ca2+
influx and it leads irreversible cell damages such as breakdown of cytoskeleton and plasma
membrane and damage of ion channels, cell adhesion molecules and surface receptors.
Therefore, calpain can cause neural cell apoptosis after SCI (Ray et al., 2003). Highly
specific inhibitor to calpain for therapeutic use has been investigated such as E-64-d (Zhang
et al., 2003) and leupeptin (Momeni and Kanje, 2006), and these inhibitors demonstrated
targets, such as apoptosis inhibitors, steroid hormone and soldium channel blockers, and
and functional recovery in traumatic injuries to the CNS. Neurotrophic factors that play an
important role in the survival, development and function of neurons, include brain-derived
neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin three (NT-3) and
neurotrophin-4/5 (NT-4/5). They belong to a class of growth factors and secreted proteins.
BDNF was originally found in the brain, but is also found in the peripheral nervous
system. It helps to support the survival of existing neurons and encourages the regrowth and
the differentiation of neurons and synapses (Waterhouse and Xu, 2009). Therefore, BDNF
has been used for treatment after CNS injuries to improve motor and sensory neuronal
31
NT-3 is in the NGF-family of neurotrophins and binds three receptors: the receptor
tyrosine kinase neurotrophin receptors (TrkC and TrkB) and low affinity nerve growth factor
receptor (LNGFR). It helps to support the survival and differentiation of existing neurons,
and encourages the growth and differentiation of new neurons and synapses. NT-3 leads to
branching and elaboration of sensory endings (Krimm et al., 2004), promotes nerve
regeneration and sensory improvement (Sahenk et al., 2005) and acts as a survival factor for
adult sensory neurons (Ljungberg et al., 1999). Since the sensory pathway runs along the
dorsal column of spinal cord and a dorsal over hemisection was used in this study, NT-3 was
chosen for delivery into spinal cord to encourage nerve survival and outgrowth after the
injury.
For axonal regeneration through the lesion site after SCI, a balance between a
permissive and favorable environment for the axons in the lesioned area is important.
Therefore, in this study, a more permissive environment was achieved by degrading the
inhibitory molecules CSPGs with chABC, while an improvement of regeneration ability was
2.6 CONCLUSIONS
combination with other therapeutic agents give promising results after SCI, although there
are some limitations and difficulties. Therefore, there is a need to develop an alternative
method to control the release of chABC temporally and spatially in vivo. In this study, we
improved the thermal stability of chABC and developed a sustained delivery scaffold for
topical delivery model combining 1) the chABC improved thermal stability by introducing
32
trehalose; 2) a temporal control method using lipid microtubules for long-term and
continuous slow release; and 3) a spatial control method utilizing agarose gel to fabricate a
This chapter briefly summarizes the background to design and develop strategies for
33
2.7 REFERENCES
Asher RA, Morgenstern DA, Shearer MC, Adcock KH, Pesheva P, Fawcett JW (2002)
Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage
cells. J Neurosci 22:2225-2236.
Asher RA, Morgenstern DA, Fidler PS, Adcock KH, Oohira A, Braistead JE, Levine JM,
Margolis RU, Rogers JH, Fawcett JW (2000) Neurocan is upregulated in injured
brain and in cytokine-treated astrocytes. J Neurosci 20:2427-2438.
Bae E, Bannen RM, Phillips GN, Jr. (2008) Bioinformatic method for protein thermal
stabilization by structural entropy optimization. Proc Natl Acad Sci U S A 105:9594-
9597.
Bandtlow CE, Schmidt MF, Hassinger TD, Schwab ME, Kater SB (1993) Role of
intracellular calcium in NI-35-evoked collapse of neuronal growth cones. Science
259:80-83.
Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, Hellenbrand
KG, Ransohoff J, Hunt WE, Perot PL, Jr., et al. (1984) Efficacy of
methylprednisolone in acute spinal cord injury. JAMA 251:45-52.
Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, Wagner FC,
Flamm ES, Eisenberg HM, Goodman JH, et al. (1985) Methylprednisolone and
neurological function 1 year after spinal cord injury. Results of the National Acute
Spinal Cord Injury Study. J Neurosurg 63:704-713.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM,
Flamm E, Leo-Summers L, Maroon J, et al. (1990) A randomized, controlled trial of
methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results
of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405-
1411.
34
Bracken MB, Shepard MJ, Collins WF, Jr., Holford TR, Baskin DS, Eisenberg HM, Flamm
E, Leo-Summers L, Maroon JC, Marshall LF, et al. (1992) Methylprednisolone or
naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of
the second National Acute Spinal Cord Injury Study. J Neurosurg 76:23-31.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M,
Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Jr., Piepmeier
J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration
of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the
treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord
Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
JAMA 277:1597-1604.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings MG,
Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Jr., Piepmeier
J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W (1998)
Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury:
1-year follow up. Results of the third National Acute Spinal Cord Injury randomized
controlled trial. J Neurosurg 89:699-706.
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon
SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury.
Nature 416:636-640.
Burgher AH, Barnett CF, Obray JB, Mauck WD (2007) Introduction of infection control
measures to reduce infection associated with implantable pain therapy devices. Pain
Pract 7:279-284.
Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA (2005) Chondroitinase ABCI
improves locomotion and bladder function following contusion injury of the rat spinal
cord. J Neurotrauma 22:226-239.
35
enzymes by trehalose and its application for the synthesis of full length cDNA. Proc
Natl Acad Sci U S A 95:520-524.
Carpenter JF, Prestrelski SJ, Arakawa T (1993) Separation of freezing- and drying-induced
denaturation of lyophilized proteins using stress-specific stabilization. I. Enzyme
activity and calorimetric studies. Arch Biochem Biophys 303:456-464.
Chau CH, Shum DK, Li H, Pei J, Lui YY, Wirthlin L, Chan YS, Xu XM (2004)
Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded
guidance channels after spinal cord injury. FASEB J 18:194-196.
Chen R (1999) A general strategy for enzyme engineering. Trends Biotechnol 17:344-345.
Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution
and acute anti-inflammatory effects of Methylprednisolone after sustained local
delivery to the contused spinal cord. Biomaterials 29:1967-1975.
Condic ML, Snow DM, Letourneau PC (1999) Embryonic neurons adapt to the inhibitory
proteoglycan aggrecan by increasing integrin expression. J Neurosci 19:10036-10043.
Crowe LM, Mouradian R, Crowe JH, Jackson SA, Womersley C (1984) Effects of
carbohydrates on membrane stability at low water activities. Biochim Biophys Acta
769:141-150.
Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. Brain Res
Bull 49:377-391.
Filpula D, Zhao H (2008) Releasable PEGylation of proteins with customized linkers. Adv
Drug Deliv Rev 60:29-49.
36
Fitch MT, Silver J (1997) Activated macrophages and the blood-brain barrier: inflammation
after CNS injury leads to increases in putative inhibitory molecules. Exp Neurol
148:587-603.
Gerndt SJ, Rodriguez JL, Pawlik JW, Taheri PA, Wahl WL, Micheals AJ, Papadopoulos SM
(1997) Consequences of high-dose steroid therapy for acute spinal cord injury. J
Trauma 42:279-284.
Gilbert RJ, McKeon RJ, Darr A, Calabro A, Hascall VC, Bellamkonda RV (2005) CS-4,6 is
differentially upregulated in glial scar and is a potent inhibitor of neurite extension.
Mol Cell Neurosci 29:545-558.
Green JL, Angell CA (1989) Phase relations and vitrification in saccharide-water solutions
and the trehalose anomaly. J Phys Chem 93:2880-2882.
Greenwald RB, Choe YH, McGuire J, Conover CD (2003) Effective drug delivery by
PEGylated drug conjugates. Adv Drug Deliv Rev 55:217-250.
Hains BC, Yucra JA, Hulsebosch CE (2001) Reduction of pathological and behavioral
deficits following spinal cord contusion injury with the selective cyclooxygenase-2
inhibitor NS-398. J Neurotrauma 18:409-423.
Hall ED, Springer JE (2004) Neuroprotection and acute spinal cord injury: a reappraisal.
NeuroRx 1:80-100.
Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK (1992) Biochemistry and
pharmacology of lipid antioxidants in acute brain and spinal cord injury. J
Neurotrauma 9 Suppl 2:S425-442.
Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov
2:214-221.
37
Hedoux A, Willart JF, Paccou L, Guinet Y, Affouard F, Lerbret A, Descamps M (2009)
Thermostabilization mechanism of bovine serum albumin by trehalose. J Phys Chem
B 113:6119-6126.
Houle JD, Tom VJ, Mayes D, Wagoner G, Phillips N, Silver J (2006) Combining an
autologous peripheral nervous system "bridge" and matrix modification by
chondroitinase allows robust, functional regeneration beyond a hemisection lesion of
the adult rat spinal cord. J Neurosci 26:7405-7415.
Huang WC, Kuo WC, Cherng JH, Hsu SH, Chen PR, Huang SH, Huang MC, Liu JC, Cheng
H (2006) Chondroitinase ABC promotes axonal re-growth and behavior recovery in
spinal cord injury. Biochem Biophys Res Commun 349:963-968.
Hugenholtz H (2003) Methylprednisolone for acute spinal cord injury: not a standard of care.
CMAJ 168:1145-1146.
Israelachvili J (1997) The different faces of poly(ethylene glycol). Proc Natl Acad Sci U S A
94:8378-8379.
Jain A, Kim YT, McKeon RJ, Bellamkonda RV (2006) In situ gelling hydrogels for
conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord
injury. Biomaterials 27:497-504.
Johnson WE, Caterson B, Eisenstein SM, Hynds DL, Snow DM, Roberts S (2002) Human
intervertebral disc aggrecan inhibits nerve growth in vitro. Arthritis Rheum 46:2658-
2664.
38
Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans
neurocan, brevican, phosphacan, and versican are differentially regulated following
spinal cord injury. Exp Neurol 182:399-411.
Kastin AJ, Pan W (2005) Targeting neurite growth inhibitors to induce CNS regeneration.
Curr Pharm Des 11:1247-1253.
Kaushik JK, Bhat R (2003) Why is trehalose an exceptional protein stabilizer? An analysis of
the thermal stability of proteins in the presence of the compatible osmolyte trehalose.
J Biol Chem 278:26458-26465.
Kim BG, Dai HN, Lynskey JV, McAtee M, Bregman BS (2006) Degradation of chondroitin
sulfate proteoglycans potentiates transplant-mediated axonal remodeling and
functional recovery after spinal cord injury in adult rats. J Comp Neurol 497:182-198.
Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor
antagonists: discovery, development, and use in patients with acromegaly. Endocr
Rev 23:623-646.
Krekoski CA, Neubauer D, Zuo J, Muir D (2001) Axonal regeneration into acellular nerve
grafts is enhanced by degradation of chondroitin sulfate proteoglycan. J Neurosci
21:6206-6213.
Krimm RF, Davis BM, Woodbury CJ, Albers KM (2004) NT3 expressed in skin causes
enhancement of SA1 sensory neurons that leads to postnatal enhancement of Merkel
cells. J Comp Neurol 471:352-360.
Ljungberg C, Novikov L, Kellerth JO, Ebendal T, Wiberg M (1999) The neurotrophins NGF
and NT-3 reduce sensory neuronal loss in adult rat after peripheral nerve lesion.
Neurosci Lett 262:29-32.
Lo Conte L, Ailey B, Hubbard TJ, Brenner SE, Murzin AG, Chothia C (2000) SCOP: a
structural classification of proteins database. Nucleic Acids Res 28:257-259.
Martinon S, Ibarra A (2008) Pharmacological neuroprotective therapy for acute spinal cord
injury: state of the art. Mini Rev Med Chem 8:222-230.
39
Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S (2002) Aggrecan
glycoforms contribute to the molecular heterogeneity of perineuronal nets. J Neurosci
22:7536-7547.
McKeon RJ, Hoke A, Silver J (1995) Injury-induced proteoglycans inhibit the potential for
laminin-mediated axon growth on astrocytic scars. Exp Neurol 136:32-43.
McKeon RJ, Schreiber RC, Rudge JS, Silver J (1991) Reduction of neurite outgrowth in a
model of glial scarring following CNS injury is correlated with the expression of
inhibitory molecules on reactive astrocytes. J Neurosci 11:3398-3411.
Meilander NJ, Pasumarthy MK, Kowalczyk TH, Cooper MJ, Bellamkonda RV (2003)
Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J
Control Release 88:321-331.
Momeni HR, Kanje M (2006) Calpain inhibitors delay injury-induced apoptosis in adult
mouse spinal cord motor neurons. Neuroreport 17:761-765.
Moon LD, Asher RA, Rhodes KE, Fawcett JW (2001) Regeneration of CNS axons back to
their target following treatment of adult rat brain with chondroitinase ABC. Nat
Neurosci 4:465-466.
40
Pindzola RR, Doller C, Silver J (1993) Putative inhibitory extracellular matrix molecules at
the dorsal root entry zone of the spinal cord during development and after root and
sciatic nerve lesions. Dev Biol 156:34-48.
Properzi F, Carulli D, Asher RA, Muir E, Camargo LM, van Kuppevelt TH, ten Dam GB,
Furukawa Y, Mikami T, Sugahara K, Toida T, Geller HM, Fawcett JW (2005)
Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-
related cytokines and enhanced in axon-growth inhibitory glia. Eur J Neurosci
21:378-390.
Ray SK, Hogan EL, Banik NL (2003) Calpain in the pathophysiology of spinal cord injury:
neuroprotection with calpain inhibitors. Brain Res Brain Res Rev 42:169-185.
Remmele RL, Jr., Nightlinger NS, Srinivasan S, Gombotz WR (1998) Interleukin-1 receptor
(IL-1R) liquid formulation development using differential scanning calorimetry.
Pharm Res 15:200-208.
Rudge JS, Silver J (1990) Inhibition of neurite outgrowth on astroglial scars in vitro. J
Neurosci 10:3594-3603.
Rudolph AS, Stilwell G, Cliff RO, Kahn B, Spargo BJ, Rollwagen F, Monroy RL (1992)
Biocompatibility of lipid microcylinders: effect on cell growth and antigen
presentation in culture. Biomaterials 13:1085-1092.
Ryan MJ KK, Tilley BC, Lotvin JA (1994) Cloning and expression of the chondroitinase I
and II genes from Proteus vugaris. Patent WO.
41
Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, Mendell
JR (2005) NT-3 promotes nerve regeneration and sensory improvement in CMT1A
mouse models and in patients. Neurology 65:681-689.
Sampedro JG, Guerra G, Pardo JP, Uribe S (1998) Trehalose-mediated protection of the
plasma membrane H+-ATPase from Kluyveromyces lactis during freeze-drying and
rehydration. Cryobiology 37:131-138.
Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA
microspheres. Adv Drug Deliv Rev 28:5-24.
Singer MA, Lindquist S (1998) Thermotolerance in Saccharomyces cerevisiae: the Yin and
Yang of trehalose. Trends Biotechnol 16:460-468.
Snow DM, Letourneau PC (1992) Neurite outgrowth on a step gradient of chondroitin sulfate
proteoglycan (CS-PG). J Neurobiol 23:322-336.
Snow DM, Steindler DA, Silver J (1990a) Molecular and cellular characterization of the glial
roof plate of the spinal cord and optic tectum: a possible role for a proteoglycan in the
development of an axon barrier. Dev Biol 138:359-376.
Snow DM, Lemmon V, Carrino DA, Caplan AI, Silver J (1990b) Sulfated proteoglycans in
astroglial barriers inhibit neurite outgrowth in vitro. Exp Neurol 109:111-130.
42
So KF, Cho EY. (1989) Advances in neural regeneration. Ann R Australas Coll Dent Surg
10:53-61.
Spargo BJ, Cliff RO, Rollwagen FM, Rudolph AS (1995) Controlled release of transforming
growth factor-beta from lipid-based microcylinders. J Microencapsul 12:247-254.
Steinmetz MP, Horn KP, Tom VJ, Miller JH, Busch SA, Nair D, Silver DJ, Silver J (2005)
Chronic enhancement of the intrinsic growth capacity of sensory neurons combined
with the degradation of inhibitory proteoglycans allows functional regeneration of
sensory axons through the dorsal root entry zone in the mammalian spinal cord. J
Neurosci 25:8066-8076.
Taneja S, Ahmad F (1994) Increased thermal stability of proteins in the presence of amino
acids. Biochem J 303 ( Pt 1):147-153.
Tang X, Davies JE, Davies SJ (2003) Changes in distribution, cell associations, and protein
expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and
tenascin-C during acute to chronic maturation of spinal cord scar tissue. J Neurosci
Res 71:427-444.
Thomas BN, Safinya CR, Plano RJ, Clark NA (1995) Lipid Tubule Self-Assembly: Length
Dependence on Cooling Rate Through a First-Order Phase Transition. Science
267:1635-1638.
Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs
22:315-329.
43
Wilson MT, Snow DM (2000) Chondroitin sulfate proteoglycan expression pattern in
hippocampal development: potential regulation of axon tract formation. J Comp
Neurol 424:532-546.
Yick LW, Cheung PT, So KF, Wu W (2003) Axonal regeneration of Clarke's neurons
beyond the spinal cord injury scar after treatment with chondroitinase ABC. Exp
Neurol 182:160-168.
Yick LW, Wu W, So KF, Yip HK, Shum DK (2000) Chondroitinase ABC promotes axonal
regeneration of Clarke's neurons after spinal cord injury. Neuroreport 11:1063-1067.
Zhang SX, Bondada V, Geddes JW (2003) Evaluation of conditions for calpain inhibition in
the rat spinal cord: effective postinjury inhibition with intraspinal MDL28170
microinjection. J Neurotrauma 20:59-
44
CHAPTER 3
(Partially published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the National
Spinal cord injury (SCI) triggers cellular and molecular signal cascades which,
amongst other things, induce growth cone inhibitors and result in regenerative failure.
Chondroitin sulfate proteoglycans (CSPGs) are upregulated and accumulate around lesion
sites after SCI and are major inhibitors of axonal regeneration. To overcome the inhibitory
effect of CSPGs, modification or digestion of CSPGs has been explored. It has been reported
that chondroitinase ABC (chABC) can digest glycosaminoglycan chains on CSPGs and
enhance regeneration when delivered into lesion sites (Bradbury et al., 2002). However,
chABC has a crucial limitation; it is thermally sensitive and at body temperature, 37ºC, its
enzymatic activity is significantly attenuated within 72 hours (Tester et al., 2007). This
necessitates the use of multiple or continuous infusions with a pump to maintain enzymatic
functionality for periods as long as two weeks. However, maintaining these infusion systems
is invasive and clinically problematic. Here, to overcome the current limitations, we report: 1)
strategy for delivery of chABC in vivo over a period of 2 weeks or longer. By adding a
protein stabilizer, trehalose, the thermostability of chABC was improved and chABC
45
maintained its enzymatic activity for 4 weeks. Enzymatic activity and conformational change
were assayed by functional and structural tests such as dimethylmethylene blue staining of
dichroism. A scaffold consisting of lipid microtubules and agarose gel was used for sustained
and spatially controlled release of thermally stabilized chABC in vitro. chABC released from
the gel-microtubule scaffold showed enzymatic activity for 2 weeks. These results have
important implications for strategies that aim to digest CSPGs as a means of reducing growth
3.1 INTRODUCTION
Physical damage to the adult central nervous system (CNS) often leads to permanent
functional loss due to the inability of mature axons to regenerate. A major impediment to
regeneration is the formation of astro-glial scar tissue at the lesion site along with a number
of myelin associated inhibitory moieties. After injury to the CNS, an inflammation process is
triggered that includes a cascade of cellular and molecular responses occurs and a glial scar is
formed around the lesioned tissue (Fawcett and Asher, 1999). Macrophages, microglia,
oligodendrocyte precursors, meningeal cells and astrocytes migrate into the lesion site and
radicals, nitric oxide, etc. The final „product‟ is a tightly interwoven glial scar formed around
chABC has been shown to promote axonal growth and functional recovery in a
number of models including spinal cord injury (Bradbury et al., 2002) and monocular
deprivation (Pizzorusso et al., 2006). It promotes axonal sprouting in both intact and injured
46
spinal cords (Barritt et al., 2006), perhaps via its action on perineural nets. Currently, chABC
is typically delivered via intrathecal injection, with infusion frequency varying from every
other day to every other week, and for time periods ranging from 2 weeks up to 6 weeks
(Chau et al., 2004; Caggiano et al., 2005; Houle et al., 2006; Huang et al., 2006). Some
groups inject chABC in combination with other therapeutic agents (Tropea et al., 2003) or in
combination with cell transplantation, such as cells from E14 fetal spinal cords (Kim et al.,
2006) or autologous peripheral nerve grafts (Houle et al., 2006), to obtain a synergistic effect.
However, there are several limitations to using chABC in vivo. ChABC is thermally
sensitive at body temperature, and loses 50% of its enzymatic activity after 1 hour of
function is lost within 3-5 days (Tester et al., 2007). Generally, CSPGs are upregulated and
accumulate in the lesion site for at least 2 weeks after the primary injury. Therefore for
chABC to remove CSPGs, it would need to be delivered for at least two weeks intrathecally
through pumps to provide a „fresh‟ supply of enzyme. Another limitation is that the diffusion
of chABC into deep regions of the cord is limited when delivered intrathecally. Because of
this delivery method the drug flows through intrathecal space and washes away quickly,
and trehalose could give a longer lifetime to chABC. The concentration of trehalose was
develop a sustained and local delivery system for providing bioactive agents, an agarose
47
hydrogel and lipid microtube was used. With the agarose hydrogel and lipid microtube
mediated delivery system, the release of the drug can be temporally and spatially controlled
by the combination of the concentration or type of agarose gel and the length of the lipid
microtube (Meilander et al., 2001). Agarose gel was used to construct an implantable
delivery carrier in vivo embedded with either lipid microtubes (Jain et al., 2006) or polymer
nanoparticles (Chvatal et al., 2008; Kim et al., 2009). This is referred to as the „hydrogel-
microtube delivery system‟. Using both trehalose and the hydrogel-microtube delivery
system, a sustained and local release of chABC and neurotrophine three (NT-3) was achieved.
In this study, we improved the thermal stability of chABC and developed agarose gel
determined whether trehalose can be used as a protein stabilizer to improve the thermal
stability of chABC, and ultimately increase the lifetime of enzymatic activity at body
develop delivery scaffold and subsequently examined as a drug delivery system for spatio-
temporally controlled release in vitro. Last, we showed an alternative approach that will
allow us to apply chABC as a therapeutic agent in vivo, as described later in chapter 4 and 5.
Because of its exceptional ability to stabilize and maintain the enzymatic activity of a
number of proteins, trehalose was used to stabilize chABC at body temperature (37 ºC)
(Kaushik and Bhat, 2003). To determine the proper concentration of trehalose for stabilizing
48
were tested for their ability to digest the GAG chains of a specific CSPG, decorin, which
consists of a core protein and a CS-GAG chain. Various concentrations of trehalose (20, 50,
100, 250, 500 mM and 1 M) were prepared in 1X phosphate buffered saline (PBS). chABC
(2U/0.5ml; 250ng) was mixed with these trehalose concentrations and each mixture was
incubated for 1, 2, 3 or 4 weeks in a 37 ºC water bath. After co-incubating for different time
durations of trehalose and chABC at 37 ºC, 10 µl of decorin (5 µg) was added, incubated at
37 ºC for 4 additional hours and the resultant products were analyzed with sodium dodecyl
When intact, decorin appears as a large molecular weight smear on an SDS-PAGE gel.
A tighter and lower molecular weight decorin band after incubation with chABC would
indicate preservation of chABC enzymatic activity. chABC without trehalose was used as a
negative control and was incubated at 37 ºC for the same incubation durations, mixed with
decorin, and incubated at 37 ºC for an additional 4 hours. After incubating, the mixtures were
diluted 1:1 with Tris-SDS sample buffer containing 5% β-mercaptoethanol and were further
incubated for 4 minutes at 95 ºC to denature the protein. The gel electrode assembly was
placed in an electrophoresis chamber (BIORAD) and the chamber was filled with Tris
running buffer. 20 µl of the prepared samples was loaded into each lane of SDS gradient gel
Silver staining was conducted to visualize separated proteins. Because the enzymatic
thermostability of chABC depends on lot and time (Tester et al., 2007), all experiments in
this study were performed with chABC from the same lot.
49
3.2.2 SILVER STAINING PROCEDURE
After running on SDS-PAGE, the gel was fixed in a solution containing methanol,
acetic acid, and water in a 45:5:50 ratio for 90 min and washed with water for 20 min twice.
The gel was washed with 0.02 sodium thiosulfate (Na2S2O3·5H2O) for 3 min and with
water for 30 sec twice, then washed with 0.1 % silver nitrate for 30 min and with water for
30 sec. A developing solution containing 2.5 % sodium carbonate/ 0.02% formaldehyde was
added. The gel was developed for 2-4 min and protein bands generally appeared within 30
sec. The developing solution was removed before overdevelopment and a solution containing
1 % acetic acid was added to quench the reaction. After rinsing with water, the gel was
was used to quantify CS-GAGs that remained after digestion of decorin with chABC. Diluted
chABC (40mU) in 1X PBS (200µl) was mixed with 1 M of trehalose and incubated at 37 ºC
to subject it to thermal stress. 10 µl of incubated chABC solution was sampled for analysis
on day 1, 3, 7 and 14. The sampled chABC/trehalose was then mixed with 10µg of decorin
and incubated at 37 ºC for 10 minutes. Next, the DMMB reagent was added and absorbance
was measured on a Microplate Reader (BIO-TEK Instruments, Inc.). The same concentration
of chABC/trehalose without added decorin was measured as the background on the same
plate and the measured background absorbance was subtracted from absorbance of the other
samples. chABC in 1X PBS without trehalose was prepared to determine the degree to which
the enzymatic activity of chABC is improved by adding trehalose. The absorbance of decorin
50
digested by fresh chABC was considered to represent 100% of enzymatic activity. The
percentage of sample absorbance relative to this standard was calculated and a deactivation
curve was plotted. The absorbance of trehalose in 1X PBS at the same concentration as above
was measured to make sure that trehalose does not interfere DMMB results.
Hollow and open-ended lipid microtubes (Fig. 3.1.) were fabricated using 1,2-bis-
Alabaster, AL) as previously described (Meilander et al., 2001; Meilander et al., 2003).
Briefly, the lipid was dissolved in 70% ethanol at a concentration of 1 mg/ml. The solution
programmed water bath (Thermo NESLAB, Portsmouth, NH) for 48 hours. During this
cooling procedure, the microtubes self-assembled into hollow structures (Spargo et al., 1995;
Meilander et al., 2001). The average length of microtube can be controlled by modifying the
cooling process (Lando et al., 1990; Thomas et al., 1995). After 2 weeks of incubation at
room temperature, 50 mM (18.9 mg/ml) of trehalose was added to the microtube solution,
mixed gently and incubated overnight to support the stability of the lipid microtube structure.
The microtube solution was centrifuged for 5 min at 3000 rpm, dried overnight in a
biological hood for complete lyophilization. Microtubes were loaded with chABC, NT-3 or
P‟ase in buffer, 1 M trehalose in 1X PBS, and incubated overnight at 4 ºC to allow for full
rehydration. Microtubes were transferred to a new tube and extra buffer, 1 X PBS, was added
51
Figure 3.1. Micrograph of lipid microtubes formed from DC8,9PC lipid in
bright field microscopy, scale bar is 50 µm. Figure from Meilander et al.,
2001.
The loading concentration of the drug was calculated based on the loading efficiency.
The loading efficiency was defined as the ratio of the entire internal volume of the
microtubes to the volume of the drug solution added to lyophilized microtubes (Meilander et
al., 2001). Figure 3.2 shows a histogram of the lengths of microtubes used in this study. The
average length was about 37 µm (0.5 µm of inner diameter) and the total number of
microtubes from 1 mg of lipid was approximately 1 × 108. Therefore, the total inside volume
of microtubes yielded from 1 mg of lipid was 0.75 µl. To increase the loading efficiency, we
tried to increase the internal volume of lipid microtubes by using more lipid solution,
52
increasing the surface area of lyophilized microtubes for more efficient rehydrating with the
500
Number of Microtubes
400
300
200
100
SCAFFOLD
SDS-PAGE was used to examine any potential adverse effects of the lipid microtubes
on chABC as a carrier for sustained release, such as loss of enzymatic activity. The DMMB
53
assay was used to characterize the release profile of chABC from microtubes. After preparing
microtubes loaded with chABC (~20 mU) and 1 M trehalose, the microtubes were co-
incubated with decorin (5 µg/200 µl). After 4 hours at 37 ºC, the co-incubated samples were
centrifuged and the supernatant was analyzed by SDS-PAGE as described in the section 3.2.1.
hydrogel, was dissolved in 1X PBS at a concentration of 1.2% (w/v) (Jain et al., 2006; Dodla
and Bellamkonda, 2008). After it was cooled below 37 ºC, the gel was mixed with an equal
volume of microtubes loaded with chABC/ 1M trehalose, placed in a 96-well plate, and
gelled at 4 ºC. The final working concentration of the gel was 0.6% (w/v). After the mixture
gelled, 1X PBS was added above the mixture and incubated in a 37 ºC incubator for up to 2
weeks. During this incubation, the supernatant was collected and replaced with fresh 1X PBS
every other day. The collected supernatant was mixed with decorin, incubated at 37 ºC and
analyzed with DMMB assay as described in the section 3.2.3. The same measurement was
conducted with microtubes loaded with P‟ase (50 ng; same amount as chABC) and trehalose
as an enzyme control.
The delivered amount can be determined by calculating the loading efficiency, which
is the ratio between the loaded volume of therapeutic agent and the entire internal volume of
the microtubes. After the release profile of the agent loaded microtubes is measured in vitro,
the daily delivered amount of agent in vivo can be predicted. Currently, there is no
54
commercially available kit for quantifying chABC levels or antibody to chABC, therefore,
the release profile of chABC was determined via SDS-PAGE and silver staining. The
samples of chABC released from the hydrogel-microtube mixture were prepared as described
in section 3.2.6, and the amount of chABC was determined via SDS-PAGE as described in
section 3.2.1 and silver staining as described in the section 3.2.2. Various different amounts
of chABC were prepared as a standard and run on SDS-PAGE at the same time with the
collected samples. Intensity measurements of the collected samples and chABC standards
were detected using a Microplate Reader (BIO-TEK Instruments, Inc.). The amount of the
released chABC was determined by the standard curve and the release profile was obtained.
NT-3 was loaded into lipid microtubes and the release profile of NT-3 was
determined by using methods similar to those previously published (Jain et al., 2006). An
NT-3 Sandwich ELISA Kit (Chemicon) was used to quantify the NT-3 release profile. NT-3
(PeproTech Inc.) containing microtubes were mixed with SeaPlaque® agarose gel, placed in
a 96-well plate, and cooled for gelation (30 ng per plate). The final working concentration of
the gel was 0.6 % (w/v). During incubation in a 37 ºC incubator for 2 weeks, the supernatant
was collected and replaced with fresh PBS every other day after sampling at day 1 and stored
at -80 ºC. The retrieved supernatants were pooled for the NT-3 ELISA and absorbance
measurements of the samples were taken at 450 nm using a Microplate Reader (BIO-TEK
Instruments, Inc.). The amount of the NT-3 was determined by the standard curve and the
55
3.2.9 ANALYSIS OF TEMPERATURE DEPENDENT CONFORMATION OF CHABC
destabilization of chABC, we conducted circular dichroism (CD) studies with and without
trehalose stabilization. chABC was dissolved into 50 mM sodium phosphate (pH 7.4) and
placed in 10 mm light path length quartz cells. Scans collected measurements from between
195 and 300 nm with a 1nm bandwidth. For the denaturation curve, scans collected
measurements from between 5 and 85 ºC at a wavelength of 222 nm with a scan rate of 2.5
ºC/min. Four scans were averaged for each running condition. The transient temperatures
between fresh chABC in buffer and chABC in trehalose solution were compared.
3.3 RESULTS
chABC by evaluating its ability to digest the CSPG decorin followed by SDS-PAGE.
Decorin, our model CSPG, has a simple molecular structure consisting of one chondroitin or
dermatan sulfate GAG chain on its core protein. Intact decorin migrates as a larger molecular
weight broad smear on an SDS-PAGE gel (Fig. 3.3, Lane 3). A tighter and lower molecular
weight decorin band after digestion by chABC indicates preservation of chABC activity.
When the CS-GAG chain of decorin was digested by chABC, the core protein migrates at
~40-45 kDa (Fig. 3.3, Lane 1), and chABC alone migrates between 97 kDa and 116 kDa (Fig.
3.3, Lane 4). chABC pre-incubated for 24 hours at 37 ºC retained its ability to degrade
decorin (Fig. 3.3, Lane 2), but chABC lost the ability to completely degrade decorin GAG
56
chains after 1 week of pre-incubation at 37 º (Fig. 3.3, Lane 5). In contrast, following
incubation with 1 M trehalose at 37 ºC for one week, chABC retained its ability to degrade
1 2 3 4 5 6
ENZYMATIC ACTIVITY
trehalose, from 20 mM to 1 M, were evaluated for their ability to preserve chABC enzymatic
57
1 2 3 4 5 6
1 2 3 4 5 6 7
58
To investigate whether trehalose can preserve chABC activity at 37 ºC for longer
periods, 1M trehalose-chABC solutions were pre-incubated for 4 weeks at 37 ºC, and then
added to decorin for digestion. In figure 3.5, Lane 1 demonstrates that after 4 weeks of pre-
incubation with 1 M trehalose, chABC digested decorin, and confirms the ability of trehalose
ºC without trehalose, chABC lost its enzymatic activity (Fig. 3.5, Lane 2). Decorin incubated
with fresh chABC (Fig. 3.5, Lane 3) and intact decorin (incubated for 4 hours at 37 ºC; Fig.
3.5, Lane 4) were run as controls at the same time. P‟ase was used as a control enzyme, and
when decorin was incubated with P‟ase at 37 ºC (Fig. 3.5, Lane 6), no decorin digestion was
observed as expected. P‟ase was not shown (P‟ase alone; Fig. 3.5, Lane 7) because molecular
weight of P‟ase (28 kDa) is out of range of this molecular standard weight.
CONFORMATIONAL STABILITY
Deactivation profiles of chABC enzymatic activity with and without trehalose over
time were evaluated with by the DMMB assay (Fig 3.6). At every time point except day 1,
there was a statistically significant difference between control and trehalose treated samples.
The enzymatic activity of chABC was maintained up to day 15 with trehalose. In comparison
however, without trehalose, chABC quickly lost its enzymatic activity after day 3 and was
constant kd was evaluated by assuming a two-state transition between native state (N), to
ND
59
dN/dt = − kbN; N= N0exp(− kbt)
where N0 represents initial N and the first-order kinetics was adapted (the dotted line in
figure 3.6). The deactivation rate constant of chABC was computed to be 0.27 [day-1;
R2=0.98]. The slope of the decline in chABC activity when it is thermostabilized by trehalose
is gentle and not precipitous and the kinetic deactivation constant of trehalose-chABC was
chABC as a function of temperature with and without trehalose were quantified by CD (Fig.
concentration of native and unfolded forms; therefore CD has been applied to protein folding
K = α / (1− α) (1)
where K is the equilibrium constant of folding, α is the friction folded, ∆G is the free energy
of folding, R is the gas constant, T is temperature (Kelvin), ∆H is the enthalpy of folding and
∆S is the entropy of folding. θobs represents the observed ellipticity, a1 is fully folded
(maximum) θobs and a2 is fully native (minimum) θobs. Based on these equations, ∆H and the
midpoint transition temperature, Tm, were calculated by fitting the best curve to θobs.
60
Figure 3.6. Kinetic analysis of chABC deactivation by DMMB assay. The
X axis represents days and the Y axis represents percentage of digested
decorin. Asterisks denote a significant difference from chABC in 1X PBS
(P < 0.05) and data represent mean ± SEM. The dotted line represents the
calculated deactivation curve of chABC in 1x PBS. Data are mean ± SEM.
chABC in 1X PBS (×) loses most activity within 5 days, and in contrast,
chABC in 1 M trehalose (Δ) retains its activity to degrade decorin CS-
GAG up to 15 days.
Initial values of ∆H, Tm, a1 and a2 were estimated, and calculated θ was fitted to the θobs by
curve fitting routine. The spectrum was measured at 222 nm and from 20 °C to 90 °C at the
rate of 2.5 °C/min and 1 min of delay. The Tm, ∆Hm and ∆Sm of chABC in 1 M trehalose
solution were 64.2 °C, 171 kJ∙mol-1 and 506 J K-1 mol-1 respectively, versus the Tm, ∆Hm and
∆Sm of chABC dissolved in sodium phosphate buffer were 56.2 °C, 176 kJ∙mol-1 and 533 J
61
K-1 mol-1. Therefore, the increment in the midpoint of transition, ΔTm, between the two
conditions is 8 °C, indicating that chABC‟s conformation is thermally more stable in the
presence of 1 M trehalose.
0.8
0.6
ΔA222nm
0.4
0.2
0
20 40 60 80 100
Temperature ( Cº)
62
3.3.4 LIPID MICROTUBE ENCAPSULATED CHABC IS BIOLOGICALLY ACTIVE
FOR 2 WEEKS
dimensions) can be loaded with chABC without compromising its enzymatic activity,
chABC released from fresh microtubes (without pre-incubation at 37 ºC) was tested with
SDS-PAGE (Fig. 3.8B) for its ability to digest decorin. As indicated by the digested decorin
After confirming that lipid microtubes can be used for chABC delivery, post-release
activity of chABC or P‟ase from microtubes was plotted (Fig. 3.8A) as a function of time,
and their relative enzymatic activity was measured by DMMB assay (Melrose and Ghosh,
1988; de Jong et al., 1989). 100% of digested decorin on the Y-axis represents 1X PBS with
no decorin. This release profile showed that, when combined with trehalose, chABC released
from microtubes retained its enzymatic activity up to 15 days in vitro. As expected, the
combination of the control enzyme P‟ase with trehalose did not digest of decorin.
63
(A)
(B)
64
3.3.5. RELEASE PROFILE OF MICROTUBE ENCAPSULATED NT-3 CONFIRMS A
To characterize the release profile of NT-3, NT-3 released from microtubes was
tested with NT-3 sandwich ELISA kit to measure released amount (Fig. 3.9).
50
Accumulated NT-3 (ng)
40
30
20
10
0
0 2 4 6 8 10 12 14
Days
3.4 DISCUSSION
The purpose of this study was to develop an approach that allows the application of
chABC as a therapeutic agent in vivo. chABC is one of the more promising therapeutic
interventions for SCI, however, the thermal instability of chABC compromises its potential
for in vivo application (Tester et al., 2007). In this study, we demonstrate that the enzymatic
activity of chABC could be maintained at body temperature over time and that
65
weeks remains enzymatically active in vitro. In this chapter, it is shown that this hydrogel-
chronically implanted, invasive pumps, which is minimally invasive and effectively delivers
chABC in vivo.
After 24 hour incubation at 37 ºC, the enzymatic activity of chABC, which is used in
this study, was still preserved. However after 1 week of incubation at 37 ºC, a broaden
decorin band appeared (Fig. 3.3, Lane 5), indicating that enzymatic activity was weakened
leading to incomplete digestion of CS-GAGs on decorin even after sufficient reaction time.
At body temperature chABC quickly loses most of its enzymatic activity within 5 days (the
DMMB assay; Fig. 3.6; ×-dashed line) and the retained enzymatic activity is not enough to
completely digest CS-GAG chains, though partial digestion is still possible (seen as a
broaden band in SDS-PAGE assay; Fig. 3.3). chABC typically lost most of its enzymatic
function within one week at body temperature, however the rate of enzymatic activity loss
and the amount of enzymatic activity retained depend on several factors. The SDS-PAGE
assay showed different retained activities of chABC from different lots. Other studies also
showed that enzymatic thermostability of chABC depends on lot and time (Tester et al.,
2007). Large differences exist between lots, since function can be lost anywhere from 1 day
to 2 weeks, so all experiments in this study were performed with chABC from the same lot.
sustained delivery of chABC (Cohen et al., 1991; Genta et al., 2001; Kim and Burgess, 2002;
Singh et al., 2009). Before using the lipid microtube, poly(lactic-co-glycolic acid) (PLGA)
nanoparticles were examined as drug carriers for chABC in a preliminary. The double
emulsion method was used to make PLGA nanoparticles, and is simple, takes a relatively
66
short time and is easy to store in powder form at -80 ºC after lyophilizing comparing to the
nanoparticle encapsulating chABC, the enzymatic activity of chABC released from the
PLGA particles was characterized with the same assessment described in the section 3.2.1.
However the mark band (Fig. 3.3, Lane 1) presenting core protein due to GAG chain
digestion by chABC was not observed and a broad band of decorin, similar to the one in
Lane 5 of figure 3.3, was seen in the gel. chABC lost its enzymatic activity after the
denaturation and chemical degradation during fabrication. The acidification of the internal
considered major protein stresses inducing inactivation and aggregation (van de Weert et al.,
2000; Perez-Rodriguez et al., 2003; Estey et al., 2006). During the double emulsion
particles is predominantly below pH 5.8 (detection limit in this paper, Li and Schwendeman,
2005).
Our laboratory has previously reported the use of lipid microtubes for the slow
delivery of a variety of proteins (Meilander et al., 2001), DNA (Meilander et al., 2003; Yu
and Bellamkonda, 2003; Meilander-Lin et al., 2005) and neurotrophic factors (Yu and
Bellamkonda, 2003; Jain et al., 2006) in vivo. Relative to other delivery systems such as
polyester based PLGA nanoparticles, lipid microtubes have the advantage that there is no
exposure to heat or organic solvents that might cause denaturation or degradation, during the
fabrication process. As is evident from figure 3.8B, release from lipid microtubes does not
adversely affect the enzymatic activity of chABC. In addition to that, lipid microtubes are
67
injectable either by themselves, or when embedded in thermo-reversible hydrogels as
reported in Jain et al. (2006), Dodla et al. (2008) and Chvatal et al. (2008).
thermostabilized chABC over a period of 2 weeks, with the microtubes enabling slow release
while the hydrogel localizes the tubes to the lesion site. We have developed a mathematical
model (Meilander et al., 2001), to predict the release profile of compounds with a range of
molecular weights such as myoglobin (17.8 kDa), albumin (66.4 kDa) and thyroglobulin
(660 kDa). These studies suggest that an initial burst release of protein from day 1 to day 3 is
agents of 80-100% by day 14. Further, microtubes show a stable and continuous release
profile with delivery of BDNF (Brain derived neurotrophic factor) (Jain et al., 2006), and
NT-3 (neurotrophin-3) (Dodla and Bellamkonda, 2008).As the molecular weight of chABC
(120 kDa) is within the protein molecular weight range previously tested, most of the chABC
exceptional stabilizer and widely used with proteins (Carninci et al., 1998; Kreilgaard et al.,
understood (Hedoux et al., 2009). There are several hypotheses outlining the mechanisms of
hydration (Timasheff, 2002), vitrification of solutions (Green et al., 1989) and the influence
of trehalose on the water tetrahedral hydrogen bond network (Branca et al., 1999). Previous
works have shown that surface tension of trehalose solutions increases linearly with increase
in trehalose concentration (Kita et al., 1994), and there is a strong correlation between
68
surface tension and increase in Tm (Kaushik and Bhat, 2003). Studies have shown that the
dynamic fluctuation of polar side chains at the solvent-protein interface was reduced in the
presence of trehalose (Hedoux et al., 2009). The increased surface tension or the limited
resulting in the stabilization of the tertiary structure of protein (Timasheff, 2002). In this
study, the Δ Tm of chABC (8 °C) with 1M trehalose addition is similar in range to its effects
on other enzymes such as RNase A (5.5 °C) and lysozyme (8.4 °C) (Kaushik and Bhat, 2003),
enzymatic activity. These enzymes also show an increase of ΔTm when concentration of
trehalose increases, and it describes the observation that only high concentration (500 mM
and 1 M) of trehalose preserved the enzymatic activity of chABC in this study. Therefore,
trehalose‟s ability to thermally stabilize chABC is consistent with its effects on other
enzymes.
3.5 CONCLUSIONS
can be slowly delivered by the lipid microtube-hydrogel delivery system and the released
chABC retains its enzymatically activity over two weeks in vitro. Therefore, these
provide an alternative and novel application for chABC treatment after SCI.
69
3.6 REFERENCES
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon
SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury.
Nature 416:636-640.
Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA (2005) Chondroitinase ABCI
improves locomotion and bladder function following contusion injury of the rat spinal
cord. J Neurotrauma 22:226-239.
Chau CH, Shum DK, Li H, Pei J, Lui YY, Wirthlin L, Chan YS, Xu XM (2004)
Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded
guidance channels after spinal cord injury. FASEB J 18:194-196.
Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution
and acute anti-inflammatory effects of Methylprednisolone after sustained local
delivery to the contused spinal cord. Biomaterials 29:1967-1975.
Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R (1991) Controlled delivery systems
for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 8:713-720.
Crowe LM, Mouradian R, Crowe JH, Jackson SA, Womersley C (1984) Effects of
carbohydrates on membrane stability at low water activities. Biochim Biophys Acta
769:141-150.
Dodla MC, Bellamkonda RV (2008) Differences between the effect of anisotropic and
isotropic laminin and nerve growth factor presenting scaffolds on nerve regeneration
across long peripheral nerve gaps. Biomaterials 29:33-46.
70
Estey T, Kang J, Schwendeman SP, Carpenter JF (2006) BSA degradation under acidic
conditions: a model for protein instability during release from PLGA delivery
systems. J Pharm Sci 95:1626-1639.
Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. Brain Res
Bull 49:377-391.
Green JL, Angell CA (1989) Phase relations and vitrification in saccharide-water solutions
and the trehalose anomaly. J Phys Chem 93:2880-2882.
Houle JD, Tom VJ, Mayes D, Wagoner G, Phillips N, Silver J (2006) Combining an
autologous peripheral nervous system "bridge" and matrix modification by
chondroitinase allows robust, functional regeneration beyond a hemisection lesion of
the adult rat spinal cord. J Neurosci 26:7405-7415.
Huang WC, Kuo WC, Cherng JH, Hsu SH, Chen PR, Huang SH, Huang MC, Liu JC, Cheng
H (2006) Chondroitinase ABC promotes axonal re-growth and behavior recovery in
spinal cord injury. Biochem Biophys Res Commun 349:963-968.
Jain A, Kim YT, McKeon RJ, Bellamkonda RV (2006) In situ gelling hydrogels for
conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord
injury. Biomaterials 27:497-504.
Kaushik, J. K., and Bhat, R. (1998) Thermal stability of proteins in aqueous polyol solutions.
J. Phys. Chem. B 102, 7058–7066
Kaushik, J. K., and Bhat, R. (1999) A mechanistic analysis of the increase in the thermal
stability of proteins in aqueous carboxylic acid salt solutions. Protein Sci. 8, 222–233
Kaushik JK, Bhat R (2003) Why is trehalose an exceptional protein stabilizer? An analysis of
the thermal stability of proteins in the presence of the compatible osmolyte trehalose.
J Biol Chem 278:26458-26465.
Kim BG, Dai HN, Lynskey JV, McAtee M, Bregman BS (2006) Degradation of chondroitin
sulfate proteoglycans potentiates transplant-mediated axonal remodeling and
functional recovery after spinal cord injury in adult rats. J Comp Neurol 497:182-198.
71
Kim H, Burgess DJ (2002) Effect of drug stability on the analysis of release data from
controlled release microspheres. J Microencapsul 19:631-640.
Kita Y, Arakawa T, Lin TY, Timasheff SN (1994) Contribution of the surface free energy
perturbation to protein-solvent interactions. Biochemistry 33:15178-15189.
Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF (1998) Effects of additives
on the stability of recombinant human factor XIII during freeze-drying and storage in
the dried solid. Arch Biochem Biophys 360:121-134.
Lando JB, Hansen JE, Sudiwala RV, Rickert SE (1990) The formation of polymerizable
tubules. Polym Adv Technol 1:27-32.
Meilander-Lin NJ, Cheung PJ, Wilson DL, Bellamkonda RV (2005) Sustained in vivo gene
delivery from agarose hydrogel prolongs nonviral gene expression in skin. Tissue Eng
11:546-555.
Meilander NJ, Pasumarthy MK, Kowalczyk TH, Cooper MJ, Bellamkonda RV (2003)
Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J
Control Release 88:321-331.
Melrose J, Ghosh P (1988) The quantitative discrimination of corneal type I, but not skeletal
type II, keratan sulfate in glycosaminoglycan mixtures by using a combination of
dimethylmethylene blue and endo-beta-D-galactosidase digestion. Anal Biochem
170:293-300.
Spargo BJ, Cliff RO, Rollwagen FM, Rudolph AS (1995) Controlled release of transforming
growth factor-beta from lipid-based microcylinders. J Microencapsul 12:247-254.
72
Tester NJ, Plaas AH, Howland DR (2007) Effect of body temperature on chondroitinase
ABC's ability to cleave chondroitin sulfate glycosaminoglycans. J Neurosci Res
85:1110-1118.
73
CHAPTER 4
(Partially as published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the
the lesion site after spinal cord injury (SCI), and are major inhibitors of regeneration. To
chondroitinase ABC (chABC) has been explored. chABC digests glycosaminoglycan (GAG)
chains on CSPGs and enhances sprouting and regeneration when delivered to the lesion site.
However, chABC has a crucial limitation; it is thermally unstable at body temperature (37ºC)
and its enzymatic activity is significantly attenuated within 3 days. Therefore, multiple or
functionality for periods of 2 weeks or longer and such devices are invasive and clinically
adding a protein stabilizer, trehalose, and demonstrated that chABC maintained its enzymatic
activity for 4 weeks at 37 ºC in vitro. Also, we developed a delivery scaffold for chABC in
In this chapter, a dorsal over hemisection injury was made at thoracic vertebrae T10
in adult rats, and thermally stabilized chABC was delivered to the lesion site by a minimally
74
invasive hydrogel-microtube scaffold carrying chABC-loaded lipid microtubules at the lesion
thermostabilized chABC, animal groups treated with single injection or hydrogel scaffold
implantation of chABC, chABC/trehalose and P‟ase were included as controls. Two weeks
after surgery, the enzymatic functionality of released chABC in vivo was examined by CS-56,
The results demonstrated that thermally stabilized chABC was successfully delivered
slowly and locally without a catheter/mini-pump and the released chABC effectively
digested CSPGs in vivo and significant differences of CSPG digestion were observed in 3B3-
IR and CS-56-IR between groups. We suggest that chABC could be combined with other
4.1 INTRODUCTION
After injury, a series of cellular and molecular events occur, and results in the
permissive environment for axon regeneration. Studies have shown that CSPGs are
upregulated after injury in the CNS and neurite regrowth is inhibited by CSPGs (McKeon et
al., 1995; Stichel et al., 1995; Lemons et al., 1999; Jones et al., 2002). It has been shown that
growth cone stall or change growth orientation at the CSPG-rich region in vitro and in vivo.
modifying CSPGs and to encourage axons to regrow through the inhibitory regions around
the lesion site. Therefore, chABC has been used to treat SCI, based on the concept that
75
removing or attenuating inhibitory activity of CSPGs could promote axonal regeneration.
After promising results for axonal outgrowth were reported in vitro (Snow and Letourneau,
1992; Zuo et al., 1998) and in vivo (Yick et al., 2000; Moon et al., 2001; Bradbury et al.,
2002; Yick et al., 2003; Chau et al., 2004; Caggiano et al., 2005; Barritt et al., 2006; Houle et
al., 2006), it has received a lot of attention as a potential therapy for spinal cord injury.
chABC shows the best enzymatic activity at 37 ºC and the optimum pH is near 8.0.
At physiological conditions, body temperature 37 ºC and 7.4 pH, chABC should be suited for
in vivo usage. However, as described in the previous chapters, there are crucial limitations
when delivering chABC for SCI treatment, such as thermal stability of chABC and
difficulties with spatio-temporal control. In general, CSPGs are upregulated and deposited
around the lesion site for at least 2 weeks after the initial injury, and the CSPG-rich matrix
surrounding the lesion site persists for up to 8 weeks following injury (Jones et al., 2003).
supply would need to be delivered intrathecally for at least two weeks. Currently this is
achieved via intrathecal injection, with the infusion frequency varying from days to weeks,
and for time periods ranging from 2 to 6 weeks to compensate the rapid loss of enzymatic
T11 hemisection promotes Clarke‟s nucleus neurons to regrow beyond the injury (Yick et al.,
2000; Yick et al., 2003). Multiple or continuous infusions were also administrated, using an
osmotic mini-pump (Chau et al., 2004; Houle et al., 2006; Huang et al., 2006) and catheters
with externalized cannulas (Moon et al., 2001; Bradbury et al., 2002; Caggiano et al., 2005;
76
Diffusion of chABC into deep regions of the cord, however, is limited when delivered
intrathecally due to overflow into the intrathecal space, thereby diluting the enzyme rapidly
and necessitating concentrated infusions (from 2 U/ml to 1000 U/ml) to compensate. With
the exception of catheters with externalized cnnulas, the efficiency of CSPG digestion is
need to develop clinically viable methods for the spatially and temporally controlled delivery
microtube based minimally invasive system to deliver chABC in a temporally and spatially
Therefore, the study in chapter 4 was designed to investigate chABC‟s activity in vivo
at the lesion site after SCI when delivered via our lipid microtube-hydrogel system and
compare the CSPG digestion efficiency to a single injection of chABC. In this short term
(two week) animal study, we locally delivered chABC to the lesion site by a topical delivery
model and the dorsal over-hemisection injury was used. Thermostabilization of chABC and
development of sustained delivery scaffold were achieved previously in the chapter 3. Two
weeks after surgery, the animals were sacrificed, and the functionality of chABC released
from the gel scaffold was examined. CS-56 and 3B3 immunostaining were used to examine
the level of CSPGs and CSPG digestion by chABC‟s activity, and WFA was used to
visualize perineuronal nets, which encapsulate synapses throughout the nervous system with
CSPGs.
77
4.2 MATERIALS AND METHODS
The fabrication procedure of the lipid microtube was previously published (Meilander
et al., 2001; Meilander et al., 2003) and described in the Chapter 3, section 3.2.4. The
solution into the microtubes, and mixed with an equal amount of 2% (w/v) SeaPrep® agarose
gel (Cambrex) in 1X PBS for 1% of final gel concentration. Before mixing SeaPrep agarose
gel with the microtubes, the gel solution was filtered for sterilization and cooled to below 37
ºC to avoid deactivation of chABC or P‟ase due to high temperature. After complete gelation
at 4 ºC, each gel scaffold contained 10mU of chABC prior to being implanted in SCI animals,
235~260 g were anesthetized with 2% of isoflurane and maintained during surgery with 0.5%
of isoflurane. The surgical area was shaved and the skin and muscles were opened to expose
the thoracic vertebrae T9-T11. A single laminectomy was performed on T10 to expose the
spinal cord by removing the bone with a micro-rongeur and the dura mater was excised.
Using micro-scissors marked at 1.5 mm depth from the tip, a controlled dorsal hemisection
injury (2 mm of width x 1.5 mm of depth) was made by cutting the dorsal columns at T10.
Sustained topical delivery of thermostabilized chABC (MTC; n=8) was achieved using
methods previously published (Chvatal et al., 2008). Briefly, the SeaPrep agarose hydrogel
78
embedded with lipid microtubes loaded with either chABC/1M trehalose or chABC alone
was placed on top of the lesion site as shown schematically in figure 4.1. To stabilize the
hydrogel embedded microtubes in place, a stiffer 0.7% of SeaKem agarose hydrogel solution
was added on top. This denser gel was quickly gelled in situ by a stream of cooled air (Fig.
4.2) as described in a previous study (Jain et al., 2006). After ensuring complete gelation, the
muscles were sutured together and the skin was closed with wound clips. Figure 4.3
demonstrates the topical delivery model applied into the spinal cord lesion site.
5 µL of 1X PBS (SC; n=6) or 1 M trehalose/1X PBS (STC; n=6) was injected as „single
injection‟ conditions that have local, but not sustained delivery. 100 ng of P‟ase (Sigma) was
delivered by single injection (STP; n=6) or hydrogel-microtube scaffold (MTP; n=6) with
1M trehalose as a negative enzymatic delivery control for chABC specificity. Sham (Sham;
n=4) and trehalose loaded hydrogel scaffold conditions (MT; n=6) were also conducted. To
avoid differences in the tissue reaction caused by absence of SeaKem agarose gel, after a
single injection of agents, a pre-made SeaKem block was placed on top of the lesion site.
79
Figure 4.1. Schematic of spinal cord injury model and delivery of enzyme to
lesion site. The 1 % SeaPrep agarose gel-microtube-scaffold is implanted on
top of the lesion and covered with stiffer 0.7% SeaKem agarose gel to keep
the scaffold in place.
Figure 4.2. Schematic of gel cooling system. Tubing runs from the nitrogen
gas tank to a Styrofoam box containing 100% ethanol and dry ice, and runs
through an aluminum rod inside a tube containing dry ice to keep the
nitrogen gas cool. The cooled nitrogen gas was applied over the stiffer
agarose gel solution for in situ gelation, which covers the top of the gel-
microtube delivery scaffold. Figure from Jain et al., 2006.
80
R
A C B
C D
C
Figure 4.3. This figure demonstrates the topical delivery model applied into
the spinal cord lesion site. A) Exposed intact spinal cord at T10 level after a
single laminectomy. B) Dorsal over hemisection injury made with a single
cut to the spinal cord column. C) Gel scaffold, embedded with chABC loaded
microtubes, implanted on top of the lesion site. D) The implanted hydrogel-
microtube delivery scaffold was covered with stiffer agarose gel to stabilize
its location on top of the lesion site. (R = rostral, C = caudal)
81
Table 1. Experimental design of 2 week study with notation
Notation of
Components # of rats
groups
Agarose gel scaffold embedded with
MTC microtubes loaded with chABC and 8
trehalose
Agarose gel scaffold embedded with
MT 6
microtubes loaded with trehalose
STC Single injection of chABC with trehalose 8
SC Single injection of chABC 6
Agarose gel scaffold embedded with
MTP microtubes loaded with penicillinase and 6
trehalose
Single injection of penicillinase with
STP 6
trehalose
NoT Injury and no treatment 6
Conducted the same procedure except
Sham 4
injury with other groups
CORDS
At two weeks post-surgery, the animals were perfused transcardially with 1X PBS
followed by 4% paraformaldehyde in 1X PBS. The T9-T11 spinal cord was removed, post-
fixed in 4% paraformaldehyde and placed in 30% sucrose at 4 ºC until it sank to the bottom.
Tissues were frozen in OCT and sagittal sections were cut with a cryostat (HM 560MV
Cryostat) at 14 µm thickness. All sections were mounted in serial order onto charged
microscope slides.
82
Sections were washed with 0.5% Triton X-100 PBS for 10 min and incubated with 4%
of goat serum/0.5% Triton X-100 PBS (blocking solution) for 1 hour. The sections were
following primary antibodies were applied: an antibody to the stub protein after chABC
digestion (1:150, mouse IgM, clone 3-B-3; Seikagaku America) which recognizes
proteoglycan (1:250, mouse IgM, clone CS-56; Sigma) to identify CSPGs; glial fibrillary
acidic protein (GFAP) (1:600, polyclonal rabbit IgG; Chemicon) for astrocytes; and Wisteria
floribunda agglutinin (WFA) (5 µg/ml, biotin conjugate; Sigma) for perineuronal nets. After
primary antibody incubation, sections were washed three times with 0.5% Triton X-100 PBS
and incubated with the appropriate secondary antibodies conjugated to fluorophores for 1
hour at room temperature. The following secondary antibodies were used: goat anti-rabbit
IgG(H+L) Alexa Fluor 488 (1:200 dilution in 0.5% Triton X-100 PBS; Invitrogen) for GFAP;
goat anti-mouse IgM Alexa Fluor 594 (1:200) for 3B3 and CS-56; and streptavidin Alexa
Flour 488 for WFA. Sections treated with secondary antibody but without primary antibody
were used as staining controls. The sections were washed three times with 1X PBS and DAPI
was applied to some of the sections for 15 min at room temperature to label the cell nuclei.
The sections were washed twice with 1X PBS and then coverslipped using Fluoromount-G
hydrogel-microtube delivery system and single injection treatments, triple staining was done
with 3B3, GFAP and WFA, and adjacent sections were double stained with CS-56 and GFAP.
GFAP labeling was used to delineate the border of the astroglial scar lining the lesion site
83
(Fig. 4.4A). Images were taken on the Zeiss Axioskop 2 Plus microscope (Zeiss, Thornwood,
RESPONSE
around the lesion site, four or five micrographs were taken at 20x magnification along the
lesion site as figure 4.4A. Relative to the lesion site, two caudal and two rostral images as
well as one image underneath the lesion were used. At least four animals were chosen from
each animal group and relative fluorescent intensity was measured using ImagePro software
package (MediaCybernetics). The gross fluorescent intensity was measured for the region
and a mean value was obtained and averaged for each animal. Background intensity was
measured on each section and deducted from the measured 3B3-IR and CS-56-IR intensity.
Quantification of GFAP
To quantify the astrocyte responses, the spinal cord tissues were immunostained and
imaged at 20x magnification along the lesion site with the same exposure time and conditions.
The images were analyzed with a custom-built image analysis program (MATLAB;
Mathworks) (Jain et al., 2006). This program generates line profiles radial to the defined
interface and records the intensity of the fluorescent signal along the line profile, thus
quantifying the relative value of intensity as a function of distance from the lesion interface
(x=0) into the spinal cord (Fig. 4.4B). The number of line profiles (e.g. 30 lines), the color
(one of RGB) to be read and the lesion interface can be selected by the user. With each run,
84
the relative intensity is averaged over all the line profiles. Four scans were performed for
each staining image and the results were averaged again over all four scans. Four sections
were chosen from each animal, four animals were chosen from each animal group and at
least five images were captured. At least 80 images (five images X four spinal cord sections
X four animals) were used and the relative intensity as a function of distance was averaged
over 2400 (30 lines X 80 images) line profiles per experiment group. After this analysis, the
relative intensity was compared between groups for different distances from the interface: 0-
A B
85
4.2.5 STATISTICAL ANALYSIS
Minitab software was used to determine the statistical differences existing between
All animal protocols were approved by the Institutional Animal Care & Use
pain management, post-care and monitoring was supervised by the Animal Research
4.3 RESULTS
EFFECTIVELY IN VIVO
delivered in vivo after SIC using our lipid microtube-embedded hydrogel delivery system at
the lesion site (Fig. 4.1) was examined by CS-56 and 3B3 immunostaining. The 3B3
and therefore, can be used as a marker for CSPGs digested by chABC. The CS-56 antibody
was used to identify intact CSPG deposition. GFAP immunoreactivity (GFAP-IR) was used
to identify reactive astrocytes and in combination with either 3B3 or CS-56, to define the
lesion boundary. Two weeks after hemisection SCI, tissue sections from the MTC (hydrogel-
microtube delivery scaffold loaded with 1M trehalose/chABC; See Table 1 for notation of
groups) treated animals showed significantly strong 3B3-IR near the lesion site (Fig. 4.5E)
86
while CS-56-IR in adjacent tissue sections was diminished (Fig. 4.5D). CS-56-IR was strong
along the lesion interface in most of the tissue sections, however intensity of CS-56-IR was
significantly reduced overall for the region near the lesion with sustained chABC delivery. In
the no-treatment (NoT) group, the reverse IR was observed with strong CS-56 intensity and
no 3B3-IR (Fig. 4.5A and B). Similar patterns were observed in the rest of the other control
To determine if chABC delivery affected the integrity of PNNs in the vicinity of the
lesion site, PNNs were labeled with Wisteria floribunda agglutinin (WFA) cytochemistry in
the same tissue sections that were stained with 3B3. WFA is a lectin specific for N-
observed near the lesion site in single injection-trehalose-chABC, no treatment (Fig. 4.5C)
and other conditions except the MTC treated condition where significantly less WFA staining
was observed (Fig. 4.5F). Immunostaining of WFA, 3B3, and CS-56 showed that WFA-
PNNs were present in conditions when CS-56-IR intensity was strong and 3B3-IR was weak
or absent around the lesion site. In the MTC treated group, the 3B3 positive region where
CSPGs were degraded by chABC had no WFA-PNNs and low CS-56-IR. Therefore
sustained delivery of chABC resulted in significantly diminished PNNs close to the lesion
87
C
D E F
88
4.3.2 QUANTIFICATION OF 3B3, CS-56 AND GFAP IMMUNOSTAINING
Measurements of fluorescent pixel intensity were as used to quantify 3B3, CS-56 and
GFAP immunostaining (Fig. 4.6) using an ImagePro software and a custom-built MATLAB
routine. 3B3-IR is significantly higher in the MTC group as compared to all other groups
(Fig.4.6A, p<0.05). The average CS-56-IR is significantly lower in the MTC group than
others and there is a statistical difference for CS-56-IR between MTC and no-treatment
GFAP-IR positive astrocytes were used to define the astro-glial scar region and the
boundary of the lesion site (Fig. 4.4A). The fluorescent pixel intensity was quantified with a
line profile image analysis program developed in MATLAB (Fig. 4.4B; Jain et al., 2006); the
program measures intensity changes from the lesion interface into the spinal cord radially.
The intensity of GFAP-IR decreased from the lesion site into the cord and the number of
reactive astrocytes also decreased, and correlated positively with CS-56-IR intensity.
Analyzed intensity was divided into three bins, 0-100, 100-300 and 300-500 µm away from
the lesion interface. The GFAP-IR was lower in the MTC treated group than other groups,
and there is a significant difference between the MTC treated group and other groups; NoT,
STP and MT in 0-100 µm and 100-300 µm (Fig. 4.7, p<0.05). This data confirm that our
sustained delivery system using lipid microtubes embedded in agarose hydrogel does not
89
*
Immunostaining intensity
A 3B3
*
Immunostaining intensity
B CS-56
Figure 4.6. Quantitative image analysis of 3B3-IR and CS-56-IR fluorescent intensity.
The X axis represents each experimental condition treated for animal groups. The Y
axis represents the relative fluorescent intensity of IR. The relative fluorescent
intensity was measured alone the lesion boundary, and mean value was obtained and
averaged for each animal. (A) 3B3-IR quantitative analysis. Asterisk denotes
significant increase of 3B3-IR in MTC treatment compared to all other treatments
(p<0.05). (B) CS-56-IR quantitative analysis. Asterisks denote significant decrease of
CS-56-IR in MTC treatment when compared to NoT and STP treatments (p<0.05).
No significant differences were observed among other treatments. The data represent
the mean ± SEM.
90
200
* *
noT STP
180
MT SC
GFAP intensity
STC MTP
160
MTC
140
120
100
80
60
0 100 200 300 400 500
91
4.4 DISCUSSION
regeneration after SCI, as it limited drug delivery approaches and forced the use of infusion
pumps or catheters for delivery. In this study, we demonstrate that the enzymatic activity of
least two weeks in vivo. This study therefore demonstrates that a single treatment with of the
implanted, invasive pumps/catheters that are typically used to deliver chABC in vivo.
clinical application of chABC might require enzymatic activity over a period of weeks. Most
studies to date have delivered chABC via multiple intrathecal injections to achieve prolonged
action. The time required to reach peak deposition of CSPG at the lesion site is dependent on
the type of CSPG (Jones et al., 2003). NG2 is the predominant CSPG expressed after SCI
and reaches peak deposition between 1 and 2 weeks after injury, and the expression levels of
neurocan, brevican, and versican are elevated after SCI, peak at 2 weeks and are maintained
for 4 weeks or more. The production of several CSPGs and proteoglycan species is
differently affected by degree and type of spinal cord injury. The main deposition pattern is
that CSPG molecules are significantly elevated within 24 hours, slowly increase until they
peak and then decrease, and overall CSPG-rich matrix persists up to 2 months. We chose a
time point of 14 days after surgery to analyze the effectiveness of thermostabilized chABC
and our delivery system because overall CSPG expression levels are highest at 14 ~ 18 days
and decrease by 49 days (Iseda et al., 2008). Delivery of active agents during this period
92
would be expected to affect inflammation and cellular responses, modulate CSPGs
deposition around lesion site, and promote axonal sprouting and outgrowth.
The sustained and local delivery of chABC was achieved over a 2 week time period
using a previously characterized gel scaffold system in our laboratory. It has been
delivery system in vitro with various proteins and DNA (Meilander et al., 2001; Meilander et
al., 2003). An in situ technique is used to quickly cool and set the liquid gel, and this gel
cooling system (Fig. 4.2) allows the gel to mold into the shape of the injury site. A BDNF-
loaded hydrogel-lipid microtube delivery scaffold was used to fill the lesion cavity on the
dorsal column of the spinal cord (Jain et al., 2006), and methylprednisolone-loaded
spinal cord as described in figure 4.1 (Chvatal et al., 2008; Kim et al., 2009). This gel-
microtube system also can be combined with a conduit to provide a bridge with neurotrophic
factors for peripheral nerve regeneration (Dodla and Bellamkonda, 2008). The previous
studies and this study demonstrate that our gel-microtube based delivery system does not
chABC sustained delivery scaffold on the top of the lesion site, we avoid a second surgery
that could cause additional injury and stress to the animal. We also avoid a chronically
inserted catheter/mini-pump that could induce inflammatory mass and increase infection risk
In the MTC treated group, 3B3-IR is significantly higher compared to all other groups.
As a control, to compare the effect of sustained delivery versus single administration, a dose
of thermostabilized chABC (STC) equal to the total amount of chABC released from the
93
lipid-microtubes over 14 days was injected at the lesion site. This single injection had no
effect as determined by a lack of 3B3 staining. This data indicates that indeed sustained
release of chABC is critical either because chABC diffuses away and loses its enzymatic
activity quickly after the single injection, or because CSPGs continue to be produced over
time. In the MTC treated group, 3B3-IR is significantly higher compared to all other groups.
It is interesting that in the STC group, small bright spots of 3B3-IR were observed around the
lesion site (gray matter) possibly due to chABC digesting some CSPGs before being washed
out. Once CSPGs are digested, the turn-over is relatively slow. PNNs were also degraded by
single injection of chABC was not sufficient to break-down PNNs. In the MTC treated
spinal cord, PNNs were not observed immediately around the lesion site, but PNNs were
present approximately 1 mm away from the lesion site suggesting that thermostabilized
chABC activity was localized to the region in the immediate vicinity of the lesion.
Permissive environment
motility and decreasing cytokine secretion such as interferon-γ and tumor necrosis factor-α
(Rolls et al., 2006). The by-product modulates intracellular signaling pathways such as PKCα
and PYK2, and induces neuronal outgrowth and protects neurons against neuronal toxicity
(Rolls et al., 2004). In this study, GFAP-IR quantification demonstrates that a) there is no
elevation of inflammation response in gel scaffold treated groups, and b) GFAP-IR was
significantly lower in the MTC treated group than others (NoT, STP and MT) near the lesion
94
area (Fig. 4.7). Therefore, it is possible that chABC treatment generated disaccharidic
degradation products act as neuroprotective agents and trigger neuronal protective and
4.5 CONCLUSIONS
thermostabilized chABC digests CSPGs after SCI without aggravating the secondary injury
response. Combinational therapy of chABC and neurotrophic factors via our delivery system
could provide a synergic effect on axonal regrowth and functional recovery after SCI. This
approach obviates the need for invasive, pump mediated delivery of chABC, elegantly
enhances the thermostability and resultant efficacy of chABC in vivo, and overcomes an
important technical hurdle for the in vivo application of chABC therapy after SCI.
95
4.6 REFERENCES
Baker JR, Christner JE, Ekborg SL (1991) An unsulphated region of the rat chondrosarcoma
chondroitin sulphate chain and its binding to monoclonal antibody 3B3. Biochem J
273(Pt 1):237-239.
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon
SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury.
Nature 416:636-640.
Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA (2005) Chondroitinase ABCI
improves locomotion and bladder function following contusion injury of the rat spinal
cord. J Neurotrauma 22:226-239.
Chau CH, Shum DK, Li H, Pei J, Lui YY, Wirthlin L, Chan YS, Xu XM (2004)
Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded
guidance channels after spinal cord injury. FASEB J 18:194-196.
Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution
and acute anti-inflammatory effects of Methylprednisolone after sustained local
delivery to the contused spinal cord. Biomaterials 29:1967-1975.
Dodla MC, Bellamkonda RV (2008) Differences between the effect of anisotropic and
isotropic laminin and nerve growth factor presenting scaffolds on nerve regeneration
across long peripheral nerve gaps. Biomaterials 29:33-46.
Houle JD, Tom VJ, Mayes D, Wagoner G, Phillips N, Silver J (2006) Combining an
autologous peripheral nervous system "bridge" and matrix modification by
chondroitinase allows robust, functional regeneration beyond a hemisection lesion of
the adult rat spinal cord. J Neurosci 26:7405-7415.
Huang WC, Kuo WC, Cherng JH, Hsu SH, Chen PR, Huang SH, Huang MC, Liu JC, Cheng
H (2006) Chondroitinase ABC promotes axonal re-growth and behavior recovery in
spinal cord injury. Biochem Biophys Res Commun 349:963-968.
96
glycosaminoglycans in injured spinal cord and promotes corticospinal axonal
regrowth after hemisection but not contusion. J Neurotrauma 25:334-349.
Jain A, Kim YT, McKeon RJ, Bellamkonda RV (2006) In situ gelling hydrogels for
conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord
injury. Biomaterials 27:497-504.
Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans
neurocan, brevican, phosphacan, and versican are differentially regulated following
spinal cord injury. Exp Neurol 182:399-411.
Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH (2002) NG2 is a major chondroitin
sulfate proteoglycan produced after spinal cord injury and is expressed by
macrophages and oligodendrocyte progenitors. J Neurosci 22:2792-2803.
McKeon RJ, Hoke A, Silver J (1995) Injury-induced proteoglycans inhibit the potential for
laminin-mediated axon growth on astrocytic scars. Exp Neurol 136:32-43.
Meilander NJ, Pasumarthy MK, Kowalczyk TH, Cooper MJ, Bellamkonda RV (2003)
Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J
Control Release 88:321-331.
Moon LD, Asher RA, Rhodes KE, Fawcett JW (2001) Regeneration of CNS axons back to
their target following treatment of adult rat brain with chondroitinase ABC. Nat
Neurosci 4:465-466.
97
Rolls A, Cahalon L, Bakalash S, Avidan H, Lider O, Schwartz M (2006) A sulfated
disaccharide derived from chondroitin sulfate proteoglycan protects against
inflammation-associated neurodegeneration. FASEB J 20:547-549.
Snow DM, Letourneau PC (1992) Neurite outgrowth on a step gradient of chondroitin sulfate
proteoglycan (CS-PG). J Neurobiol 23:322-336.
Yick LW, Cheung PT, So KF, Wu W (2003) Axonal regeneration of Clarke's neurons
beyond the spinal cord injury scar after treatment with chondroitinase ABC. Exp
Neurol 182:160-168.
Yick LW, Wu W, So KF, Yip HK, Shum DK (2000) Chondroitinase ABC promotes axonal
regeneration of Clarke's neurons after spinal cord injury. Neuroreport 11:1063-1067.
98
CHAPTER 5
(Partially as published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the
CSPGs are one major class of axon growth inhibitors which are upregulated after SCI
and contribute to regenerative failure. Chondroitinase ABC (chABC) digests CS-GAG chains
on CSPGs and can thereby overcome CSPG mediated inhibition and promote axonal
regeneration when delivered at the site of injury. However, chABC loses its enzymatic
activity rapidly at 37 ºC, necessitating the use of repeated injections or local infusions with a
mini-pump or catheter for days to weeks. Maintaining these infusion systems is invasive,
chABC and developed a system for its sustained local delivery in vivo, obviating the need for
chronically implanted catheters and pumps in chapter 3. When stabilized with trehalose,
hydrogel system was used for controlled release of chABC over 2 weeks at the lesion site
following a SCI in chapter 4. The enzymatic functionality of released chABC and the cellular
and molecular responses were examined by immunostaining with 3B3, CS-56, GFAP and
WFA two weeks after injury. The results demonstrate significant differences in CSPG
99
digestion between groups treated with the chABC-loaded hydrogel microtube delivery
In this chapter, a long term study (45 days) was conducted to examine axonal
regeneration and functional recovery after chABC treatment and combination treatment with
a neurotrophic factor, NT-3. The resultant impact of the initial CSPG digestion during the
first two weeks was still present at 6 weeks following SCI when delivered by a hydrogel-
microtube delivery system. Axonal growth and functional recovery following the sustained
sprouting of 5-HT serotonergic fibers at the lesion site. We suggest that this significant
method for sustained, local delivery of chABC that is potentially effective in overcoming
neurotrophic factors enhances axonal regrowth, sprouting and functional recovery after SCI.
5.1 INTRODUCTION
After injury to the central nervous system, the lesioned axons fail to re-grow or make
functional connections (Schwab and Bartholdi, 1996). While the cellular and molecular
mechanisms of axon growth failure are active areas of research, a breakthrough clinical
therapy has yet to be developed. Injuries to the CNS induce a series of inflammatory events
100
There are many factors contributing to the failure of spontaneous regeneration; a lack
Schwab et al., 2006) and glial scar-associated CSPGs (McKeon et al., 1995; Silver and Miller,
2004), which are upregulated after injuries to the CNS and contribute to regenerative failure.
Strategies can be developed for each inhibitory factor to overcome the lack of repair capacity
after spinal cord injury. In chapter 3 and 4, we focused on developing a chABC treatment to
for chemo-attracting axons to the lesion site. Combination therapies with chABC have been
hemisected adult rats after chABC treatment (Chau et al., 2004) and an autologous peripheral
nervous system bridge with cellular matrix modified by chABC was grafted onto a
hemisection lesion (Houle et al., 2006). Synergistic effects were observed on axonal
sprouting into the dorsal column nuclei after combination treatment with chABC and NT-3
(Massey et al., 2008). Retinal fiber sprouting with combination treatment with chABC and
BDNF after denervation of the superior colliculus has been also observed (Tropea et al.,
2003). To encourage axonal outgrowth, we chose to use NT-3 with chABC. Removal of an
101
A longer 45 day study was designed to examine the functional consequences of
CSPG digestion by chABC and a combination therapy with the neurotrophic factor NT-3 via
the ability of trehalose to confer conformational stability, and that thermostabilized chABC
thermostabilized chABC and NT-3 was used to overcome the CSPG-rich astroglial barrier to
with combination delivery of chABC and NT3 were observed, and correlated well to
immunohistological evidence of axonal sprouting at the lesion site. Analysis of 5-HT sensory
fibers and CTB-labeled fibers demonstrated that chABC treatment can induce plasticity of
injured projections within the spinal cord and offers a possible mechanism of chABC-
induced functional recovery. This study therefore demonstrated that a single administration
implanted, invasive catheters or mini-pumps typically used to deliver chABC after SCI. The
combination therapy of chABC and NT-3 with our delivery method offers a potent approach
102
5.2 MATERIALS AND METHODS
Table 5.1 describes conditions and notations of experimental and control groups in
the 45 day in vivo study. In the long term study, MTC (hydrogel-microtube delivery scaffold
with 1M trehalose/P‟ase; n=6) and sham (n=4) treatment conditions were used, the other
conditions used in the short term study were excluded, and three new treatments were added.
In the short term study, a single injection of chABC did not show effective digestion of
CSPGs, and there was no significant difference from no treatment animals in the 2 week
study (in chapter 4, section 4.3.2). Therefore, single injection controls (SC – single injection
1M trehalose/chABC to the MTC treatment condition) treatment conditions were added for
the long term study. As a control to probe the sustained release enabled by lipid microtubes
trehalose was implanted on the top of the lesion site (n=6; GC); the other conditions included
lipid microtubes loaded with NT-3 (n=7; MTN; 100 ng per rat) or combination microtubes
loaded with chABC and NT-3 (n=8; MTCN) to investigate effect of combination treatment
103
The surgical procedure followed to induce injury and the delivery methods of
hydrogel-microtubes delivery scaffold were the same as for the 2-week short term study
described in the chapter 4, section 4.2.2. Briefly, adult male Sprague-Dawley rats (Charles
River) received a dorsal over-hemisection injury at the T-10 vertebral level. Sustained topical
delivery was achieved using methods previously reported (Chvatal et al., 2008) and shown in
Six weeks post-injury and 3 days before sacrificing, cholera toxin B subunit (CTB;
sigma) was injected into the right sciatic nerve for retrograde axonal tracing. Rats were
anesthetized using isoflurane gas. The thigh region on the right leg was shaved, and 2 cm of
incision was made through the skin and muscles to expose the sciatic nerve. 5 µl of 1% CTB
was slowly injected into the nerve with a 34 gauge needle (NanoFil). The muscles were
sutured and the skin closed using wound clips. 3 days after injecting the CTB, the animals
104
Table 2. Experimental design of 45 days study with notation
Notation of # of
Components
groups rats
Agarose gel scaffold embedded with
MTC 7
microtubes loaded with chABC/trehalose
Agarose gel scaffold embedded with
MTN 7
microtubes loaded with NT-3
Agarose gel scaffold embedded with
MTCN microtubes loaded with chABC/trehalose 8
and NT-3
GC Agarose gel mixed with chABC/trehalose 6
Agarose gel scaffold embedded with
MTP microtubes loaded with 6
penicillinase/trehalose
Conducted the same procedure except
Sham 4
injury with other groups
improvement in the 45 day long term study. The investigators were blinded with regard to
animal groups throughout these tests. CatWalk (Noldus), a video-based analysis system, was
used to assess locomotor deficits in voluntarily walking. Each rat voluntarily walked across
the walkway three times every week after injury. After acquiring raw data, paw prints were
labeled as right forepaw (RF), left forepaw (LF), right hindpaw (RH) and left hindpaw (LH)
and measurements of locomotion were provided by the software. Stride length, paw print
pattern and base support were chosen to examine behavior as a function of time after injury
105
for all experimental conditions. Stride length was defined as a distance between consecutive
steps with the same limb. The distance in mm between the two hind paws was defined as the
base of support and this distance is measured perpendicular to the direction of walking. The
white boxes in figure 5.1 show abnormal hindpaw print patterns and the number of abnormal
Figure 5.1. CatWalk raw data in false color mode. White boxes represent
abnormal hindpaw print patterns. The dotted lines represent the stride length
defined as a distance between consecutive steps with the same limb and the
solid line represents the base of support defined as a distance between the two
hind paws. (dark red – left hindpaw, light red – left forepaw, dark green – right
hindpaw and light green – right forepaw)
Thermal sensitivity assessment by a dynamic plantar test (Ugo Basile) was used,
identical to the method of Hargreaves et al (1988). The device measured the time taken to
elicit a flexion reflex. Each hind-paw was tested three times every week and averaged. The
animals were placed on a glass floor under which a mobile radiant infra-red heat source was
positioned at the animal‟s hind paw. When the animal withdrew its paw, the source power
106
5.2.4 TISSUE PREPARATION AND IMMUNOHISTOCHEMISTRY
At 45 days post-surgery, the animals were perfused transcardially with PBS followed
paraformaldehyde and placed in 30% sucrose at 4 ºC. Tissues were frozen and sagittal
sections were cut with a cryostat (HM 560MV Cryostat) at 14 µm thickness. All sections
Sections were washed with 0.5% Triton X-100 PBS for 10 min and incubated with 4%
of goat serum/0.5% Triton X-100 PBS (blocking solution) for 1 hour. The sections were
incubated with primary antibodies diluted in the blocking solution at 4 ºC overnight. The
following primary antibodies were applied against: CS-56 (1:250, mouse IgM; Sigma) to
identify CSPGs; glial fibrillary acidic protein (GFAP) (1:600, polyclonal rabbit IgG;
Chemicon) for astrocytes; anti-CTB (1:600; abcam); and serotonin (1:150, 5-HT, monoclonal
mouse IgG1; Abcam) for serotonergic neurons. After primary antibody incubation, sections
were washed three times with 0.5% Triton X-100 PBS and incubated with the appropriate
following secondary antibodies were used: goat anti-rabbit IgG(H+L) Alexa Fluor 594
(1:200 dilution in 0.5% Triton X-100 PBS; Invitrogen) for GFAP; goat anti-mouse IgM
Alexa Fluor 488 (1:200) for anti-CTB, 5-HT serotonin and CS-56. Sections treated with
secondary antibody but without primary antibody were used as staining controls. The
sections were washed three times with PBS and coverslipped using Fluoromount-G.
To evaluate the axonal sprouting, double staining was conducted with CTB and
GFAP or 5-HT and GFAP. Double staining of 3B3 and GFAP was also conducted to
examine the level of CSPGs. GFAP labeling was used to define the border of the astroglial
107
scar lining the lesion site (Fig. 4.4A). Images were taken on the Zeiss Axioskop 2 Plus
A montage of each tissue section stained for CTB labeled fibers was obtained at 10x
the caudal lesion interface and defined by GFAP immunoreactivity (IR). The relative
intensity of CTB labeled fibers were measured using ImagePro software (MediaCybernetics)
at 1 and 0.5 mm caudal to the start of lesion, at the start of the lesion, and 0.5 and 1 mm
rostral to the lesion. The intensity of CTB labeled fibers 1 mm caudal to the caudal edge of
the lesion was assumed to represent the total CTB fibers approaching the lesion site and the
percentage of CTB fibers stopped within the defined regions was determined by measuring
the relative intensity. Background intensity was measured on each section and deducted from
magnification from two defined regions, ventral gray matter caudal and rostral to the lesion
site, and relative fluorescent intensity was measured by ImagePro software package. The
gross fluorescent intensity was measured for the region and mean value was obtained.
Background intensity was measured on each section and deducted from the measured 5-HT
IR intensity.
108
5.2.6 STATISTICAL ANALYSIS
Minitab software was used to determine the statistical differences existing between
All animal protocols were approved by the Institutional Animal Care & Use
pain management, post-care and monitoring was supervised by the Animal Research
5.3 RESULTS
AT 6 WEEKS
To examine whether the resultant impact of the initial 2 weeks of CSPG digestion
persists in vivo after 6 weeks, CS-56 immunostaining for intact CSPGs was conducted. Tissue
sections from the MTCN treated animals showed that significantly less CS-56 expression
109
Figure 5.2. Micrograph of CS-56-IR around the lesion site at 6 weeks. (A)
MTCN and (B) MTP. CSPG-IR is significantly less in the MTCN treated
animals compared to MTP treated controls. Scale bar is 100 µm.
FUNCTION
Functional recovery was assessed by using the CatWalkTM and thermal plantar tests
throughout the 45 day period. A significant difference in locomotor function was observed
six weeks post-injury, but not earlier, and no improvement was observed with the thermal
pain threshold test in any animal groups throughout the six week testing period. All the
animal groups showed improved locomotor function throughout the testing period. At day 7
and day 14, all animals showed abnormal walking patterns, slow crossing, and abnormal paw
prints, reflecting the SCI-mediated dysfunction. Four weeks post surgery, most animals
showed a normal step sequence and the time necessary to cross the walkway decreased. A
number of abnormal hind paw prints also decreased and stride length increased due to
recovery from injury. However the differences between animals were not observed by 4
weeks.
110
Figure 5.3 showed CatWalk raw data of sham (A), MTCN (B) and MTP (C) treated
animals on the walkway in false color mode at 6 weeks. Dark red represents left hindpaw;
light red – left forepaw, dark green – right hindpaw and light green – right forepaw. As seen
on figure 5.3, hindpaws step on the print of the consecutively previous forepaw. Animals
with higher degree injuries generally fail to walk with a normal step sequence and step on the
consecutively previous forepaw print. In this study, we used a relatively moderate injury
(dorsal over hemisection), therefore, most animals showed normal step patterns. Six weeks
post-SCI surgery, there were significant differences in the stride length between treatment
conditions (Fig. 5.4). Average stride lengths (mean ± SEM) were 183.6 ± 6.91 mm for
MTCN, 172.89 ± 20.8 mm for MTC, 157 ± 18.25 mm for MTN, 152.91 ± 13.13 mm for GC
and 154.07 ± 10.11 mm for MTP at 6 weeks (See Table 2 for notation of groups). Significant
differences were observed between MTCN and GC (p = 0.019), and MTCN and MTP (p =
0.035).
At 6 weeks, the MTCN, MTC and MTN treated animals had more normal foot prints
(Fig. 5.3B) compared to MTP treated animals (white boxes in Fig. 5.3C). The sham animal
had normal foot print and the MTP animal had abnormal hindpaw prints (white box in Fig.
5.3C.). The number of abnormal hindpaw prints was counted per three step cycles and the
averages were 0.7 ± 0.3 for MTCN, 1.7 ± 0.6 for MTC, 1.8 ± 0.5 for MTN, 2.1 ± 1.3 for GC
and 3.3 ± 1.3 for MTP. The mean number of abnormal print of the single treated animals,
MTC and MTN, is less than that of animals treated by GC and MTP and the combination
treatment MTCN group, on average had even fewer abnormal foot prints. However while
these were strong trends, the differences were not significant between animal groups.
111
The distance in mm between the two hind paws was defined as the base of support
and this distance is measured perpendicular to the direction of walking. Animals tend to
show a larger base of support after SCI. At 6 weeks, the averages were 31.4 ± 4.8 mm for
MTCN, 30.7 ± 4.4 mm for MTN, 39.8 ± 8.9 mm for GC and 38.5 ± 4.5 mm for MTP, and
112
Figure 5.3. CatWalk raw data in false color mode, (A) Sham, (B) MTCN
and (C) MTP treated animals on the walkway at 6 weeks. All animal
groups show a normal step sequence. The white box in the figure C
represents an abnormal hindpaw print. Red represents left paw prints and
green represents right paw prints (dark red – left hindpaw, light red – left
forepaw, dark green – right hindpaw and light green – right forepaw).
113
210
† *
† Sham
190 MTC
MTN
Stride length (mm)
† MTCN
170
MTP
GC
150
130
110
2 week 4 week 6 week
Figure 5.4. Stride length analysis for locomotion functional recovery. Data are
mean ± SEM and asterisk denotes statistical significance between MTCN and
MTP, and between MTCN and GC (P <0.05). Sham showed significant
differences († < 0.05) compared to all other conditions throughout the testing
period, except for MTCN at 4 and 6 weeks.
114
5.3.3 SUSTAINED DELIVERY OF CHABC AND NT-3 PROMOTES SPROUTING
FIBERS
To examine anatomical regeneration in the dorsal column, CTB was injected into the
sciatic nerve and resulted in labeling of the primary apparent within the spinal cord. The
location of labeled fibers was examined; the MTP and GC treated animals had retracted
CTB-labeled fibers in the glial scar area and few fibers approached the lesion site (Fig. 5.5A).
However in the MTC, MTN and MTCN treated animals, more CTB-labeled fibers crossed
the glial scar area and approached the lesion boundary (Fig. 5.5B). CTB-labeled fibers grew
around cavities along the lesion interface (Fig. 5.5C and D; 0 to 0.5 mm interval in C and 0.5
to 1 mm interval in D) and a few fibers were observed after 0.5 mm rostral to caudal edge of
the lesion in chABC and NT-3 treated animals. However no fibers entered the lesion cavity
in any animal groups. Significantly more fibers crossed 0 and 0.5 mm rostral to the caudal
edge of the lesion in the MTCN (p=0.03 and p=0.045; p=0.049 and p=0.045, respectively)
animals compared to GC and MTP treated animals (Fig. 5.6). At one mm rostral to the caudal
edge of the lesion start, a few fibers were observed in the MTC, MTN and MTCN treated
animals, however most were not strong enough to be detected by the relative intensity
115
Figure 5.5. Micrographs of CTB labeled fibers (green) at the lesion site at
6 weeks. The dashed lines represent the lesion interface. (A) MTP and (B)
MTCN at 10 x magnification. Scale bar is 500 µm (C) An expanded figure
from the white box 0 to 0.5 mm interval in figure A, and (D) an expanded
figure from the white box in 0.5 to 1 mm interval figure B at 20 x
magnification. Arrows represent CTB labeled fibers. Scale bar is 100 µm.
116
100
MTC
% of crossed CTB-labeled fibers
80 MTN
MTCN
60 MTP
GC
40 *
20
*
0
-0.5 0 0.5 1
Distance from the caudal edge of the lesion (mm)
117
5.3.3.2 AXONAL SPROUTING AROUND THE LESION AREA: 5-HT-
IMMUNOREACTIVE FIBERS
5-HR-IR fibers in the ventral gray matter were measured to quantify the percentage of
the lesion site. More 5-HT-IR fibers were observed in the gray matter of MTC, MTN and
MTCN treated animals. The serotonergic fibers were observed in the gray mater, primarily in
the ventral horn and lamina X, and more fibers were located rostral versus caudal to the
lesion (Fig. 5.7A). The spinal cords tissues treated with chABC, NT-3 and combination of
chABC and NT-3 had higher fluorescent intensity and the 5-HT-IR fibers extended closer to
the lesion site than MTP and GC treated controls. Quantification confirmed that MTCN
treatment showed significant sprouting of serotonergic fibers caudal to the lesion versus all
other conditions (p = 0.008 for MTC, p = 0.024 for MTN, p = 0.001 for GC and p = 0.001 for
MTP); and rostral to the lesion than MTN (p = 0.015), GC (p = 0.002) and MTP (p = 0.001)
118
caudal rostral
B C
119
caudal rostral
18
*
16 MTC
14
% of 5-HT-IR fibers
MTN
12
MTCN
10
* MTP
8
GC
6
4
2
0
location to the lesion
120
5.4 DISCUSSION
A six week long term study was performed to determine whether chABC or NT-3
axonal sprouting/regeneration and improve functional recovery after SCI in the rodent model.
Also, combination treatment of chABC and NT-3 was tested via our delivery system to
evaluate whether the combination therapy can provide synergic effect on axonal regrowth
and functional recovery. CSPG deposition, axonal sprouting and behavioral improvement
combination therapy. CS-56 immunostaining shows that the resultant impact of the initial
CSPG digestion is still present at 6 weeks. Locomotor behavior improved with combinational
chABC-NT3 delivery, and correlated well with increased axonal sprouting at the lesion site.
This study demonstrates that a single treatment of thermostabilized chABC via the hydrogel-
invasive pumps typically used to deliver chABC in vivo. In addition, the combination
Once CSPGs are digested, the turn-over is relatively slow (Bruckner et al., 1998). In
the short term study, significantly decreased CSPG-IR was observed in the animals treated
with the chABC loaded hydrogel-microtube system. CS-56 immunostaining was performed
to examine whether CSPG digestion during the first two week still present. CS-56 staining at
6 weeks (Fig. 5.2) shows that little CS-56 expression persists compared to untreated controls.
This suggests that thermostabilized chABC digestion was effective early, at the peak of
CSPG production and its turn-over is slow (more likely), or that chABC activity via
microtubes is sustained for longer than 2 weeks (unlikely, but possible). In either case, the
121
chABC digestion via microtubes remains effective over a period of 6 weeks as is evident
from little CS-56 positive tissue at the 6 week time point. CSPG levels remain low up to 6
weeks post-injury, thereby facilitating sprouting and regeneration. Another study reported
similar results, showing that evidence of chABC digestion remained for at least 7 weeks in
The results demonstrated that a single treatment of chABC and NT-3 enhanced
sensory axonal sprouting, and the combination treatment enhanced more axonal sprouting
around the lesion site. The CTB labeled fibers mainly represent ascending sensory pathways
in the dorsal columns of the spinal cord. No CTB-labeled fibers entered the lesion cavity in
any treatment condition, however a significantly higher percentage of axons were approached
the lesion boundary and grew around the lesion site in the animals treated with single or
combination delivery of chABC and NT-3 compared to other groups. While some sensory
improvement was observed using the thermal pain threshold test (hindpaw withdrawal
latency to heat stimuli) in any of the animal groups during the 45 day test period. There are
two possibilities to explain the results; first, after the dorsal over hemisection cutting there
may be possibly spared fibers around the dorsal lateral fasciculus that help retain sensitivity
in all groups independent of lesion. Second, despite the significant primary afferent
sprouting in the treated animals, the sprouting was predominantly located in the dorsal white
matter and no fiber entered into the lesion site in any animal groups. Therefore, the axonal
sprouting was not enough to transmit stimuli to the dorsal horn where primary afferent
terminals are located, explaining why no differences exist between experimental groups. Our
observation is consistent with other studies. Despite robust primary afferent sprouting in
122
animals treated with chABC, no improvement of noxious thermal sensation (Barritt et al.,
2006) was observed, and transgenic mice expressed chABC under the murine gfap promoter
showed nearly complete digestion of CSPGs and robust axonal growth into the glial scar, but
no axon crossing into the lesion or motor functional recovery (Cafferty et al., 2007).
Enhanced locomotor functions were observed in the MTC and MTCN animal groups
and there were significant improvements in MTCN treated animals in terms of stride length,
but not base support or number of abnormal hindpaw patterns. Stride length is an important
parameter of locomotor efficacy as it impacts speed of locomotion (Hamers et al., 2001). The
gains in other locomotor functions were probably obscured by our choice of the relatively
demonstrated significantly higher sprouting in MTCN group relative to all other groups. As
eliciting even more significant sprouting, it is possible that the sprouted local serotonergic
spinal circuits facilitated observed locomotor improvements in stride length. This increase in
sprouting is likely due to chABC mediated digestion of CSPG-rich PNNs that surround
the digestion of CSPG-rich perineuronal nets (PNNs) (Massey et al., 2006; Galtrey et al.,
2007; Massey et al., 2008). There is evidence that this structure regulates neuronal plasticity
(Pizzorusso et al., 2002), protects encapsulated neurons (Bruckner et al., 1999) and supports
ion homeostasis (Bruckner et al., 1993). This observation is consistent with other reports that
PNN digestion by chABC leads to increased plasticity and functional improvement due to
reinnervation and sprouting; PNN breakdown in the cuneate nucleus promoted collateral
sprouting/plasticity, resulting in axonal sprouting in the forelimb afferents after SCI (Massey
123
et al., 2006) and increasing plasticity in the spinal cord improved peripheral nerve
regeneration (Galtrey et al., 2007). CSPG removal by chABC delivery in the adult visual
recovery of dendritic spine density (Pizzorusso et al., 2006). In this study we observed that
the PNN breakdown around the lesion area after chABC treatment (Fig. 4.5); motor neurons
and many interneurons are surrounded by PNNs. It may possibly have caused the increased
sprouting of serotonergic fibers, thereby increasing plasticity of spinal locomotor circuits and
increasing the density of newly-grown processes in the adult CNS ECM, and it could lead
2006) or aberrant sprouting (Barritt et al., 2006), is one major mechanism of chABC
treatment. Therefore, possible negative effects are aberrant sprouting and neuropathic pain
due to the aberrant plasticity (Woolf and Salter, 2000) or autonomic dysreflexia due to
increased plasticity (Weaver et al., 2006). These concerns have been raised previously.
Studies reported that no evidence of hyperalgesia was observed after chABC injection in to
the spinal cord (Pizzorusso et al., 2006), and no increase of connectivity of nociceptive
even after aberrant sensory fiber sprouting (Barritt et al., 2006). Therefore, it is very
important to balance between detrimental sprouting and beneficial sprouting, and the
124
In the short term study, there appears to be significant impact of chABC digestion at 2
weeks, though evidence of functional recovery for in vivo studies was not seen until at least 6
weeks. With regard to the time lag between peak CSPG deposition and first evidence of
functional recovery, axonal regrowth and sprouting can occur after CSPG digestion – hence
the lag in time between CSPG digestion and functional recovery. After injury, severed axons
retract from the lesion site, therefore, functional recovery requires axonal regrowth and
sprouting to reconnect/regain the functional pathway. Once our chABC treatment removes
axonal outgrowth, and axons can then regrow and sprout through the region. After SCI,
animals are typically allowed 6 weeks or longer to assess axonal regeneration and functional
recovery.
Our data is consistent with other studies where successful digestion of CSPGs does
not automatically lead to improved behavioral outcomes (Barritt et al., 2006; Cafferty et al.,
2007). Transgenic mice having a gfap promoter to express chABC demonstrated almost
complete CSPG digestion at the reactive astrocyte-region. Significant sensory axon sprouting
was observed, however it was not sufficient to improve motor function (Cafferty et al., 2007).
provide to favorable environment for sufficient axon regeneration. When chABC delivery is
combined with NT-3 lentivirus delivery, dramatically increased axonal extension was
observed compared to single delivery of chABC or NT-3 (Massey et al., 2008). In this study,
125
To apply this method as a clinical therapy, the practicality of chABC treatment
needs to be considered. In this study, the chABC activity was limited to 1 mm away
from lesion site and it is not clear whether this area is large enough to be clinically useful.
Because chABC is a relatively large molecule, diffusion through neural tissue and
deeper into the tissue (up to 1mm). This is because mini-pump delivery affects a larger
region, diluting the chABC, whereas our delivery system enables local delivery into the
tissue. As CSPG deposition tapers off exponentially from the lesion border, the local
delivery of chABC is relevant and effective, and sufficient diffusion (again as evident
from our 6 week CS-56 staining) occurs to effectively digest the CSPGs deposited near
the lesion site. In humans, there might be a need for greater diffusion distances as the
CSPG deposition zone may be deeper, but whether or not chABC diffusion into injured
human cord will be a limitation or not remains to be determined. The minimum clinically
determined.
5.5 CONCLUSIONS
chABC digests CSPGs after SCI without aggravating secondary injury response.
Combination therapy of chABC and NT-3 facilitated by our sustained delivery system
enhanced axonal sprouting and functional recovery after SCI. This approach elegantly
126
obviates the need for invasive, indwelling catheter/pump-mediated delivery of chABC,
127
5.6 REFERENCES
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bruckner G, Brauer K, Hartig W, Wolff JR, Rickmann MJ, Derouiche A, Delpech B, Girard
N, Oertel WH, Reichenbach A (1993) Perineuronal nets provide a polyanionic, glia-
associated form of microenvironment around certain neurons in many parts of the rat
brain. Glia 8:183-200.
Cafferty WB, Yang SH, Duffy PJ, Li S, Strittmatter SM (2007) Functional axonal
regeneration through astrocytic scar genetically modified to digest chondroitin sulfate
proteoglycans. J Neurosci 27:2176-2185.
Chau CH, Shum DK, Li H, Pei J, Lui YY, Wirthlin L, Chan YS, Xu XM (2004)
Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded
guidance channels after spinal cord injury. FASEB J 18:194-196.
Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution
and acute anti-inflammatory effects of Methylprednisolone after sustained local
delivery to the contused spinal cord. Biomaterials 29:1967-1975.
Galtrey CM, Asher RA, Nothias F, Fawcett JW (2007) Promoting plasticity in the spinal cord
with chondroitinase improves functional recovery after peripheral nerve repair. Brain
130:926-939.
Hamers FP, Lankhorst AJ, van Laar TJ, Veldhuis WB, Gispen WH (2001) Automated
quantitative gait analysis during overground locomotion in the rat: its application to
spinal cord contusion and transection injuries. J Neurotrauma 18:187-201.
128
Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for
measuring thermal nociception in cutaneous hyperalesia. Pain 32:77-88.
Houle JD, Tom VJ, Mayes D, Wagoner G, Phillips N, Silver J (2006) Combining an
autologous peripheral nervous system "bridge" and matrix modification by
chondroitinase allows robust, functional regeneration beyond a hemisection lesion of
the adult rat spinal cord. J Neurosci 26:7405-7415.
Massey JM, Hubscher CH, Wagoner MR, Decker JA, Amps J, Silver J, Onifer SM (2006)
Chondroitinase ABC digestion of the perineuronal net promotes functional collateral
sprouting in the cuneate nucleus after cervical spinal cord injury. J Neurosci 26:4406-
4414.
Massey JM, Amps J, Viapiano MS, Matthews RT, Wagoner MR, Whitaker CM, Alilain W,
Yonkof AL, Khalyfa A, Cooper NG, Silver J, Onifer SM (2008) Increased
chondroitin sulfate proteoglycan expression in denervated brainstem targets following
spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase
ABC and neurotrophin-3. Exp Neurol 209:426-445.
McKeon RJ, Hoke A, Silver J (1995) Injury-induced proteoglycans inhibit the potential for
laminin-mediated axon growth on astrocytic scars. Exp Neurol 136:32-43.
Neumann S, Woolf CJ (1999) Regeneration of dorsal column fibers into and beyond the
lesion site following adult spinal cord injury. Neuron 23:83-91.
Schwab JM, Tuli SK, Failli V (2006) The Nogo receptor complex: confining molecules to
molecular mechanisms. Trends Mol Med 12:293-297.
Schwab ME (2004) Nogo and axon regeneration. Curr Opin Neurobiol 14:118-124.
Schwab ME, Bartholdi D (1996) Degeneration and regeneration of axons in the lesioned
spinal cord. Physiol Rev 76:319-370.
Silver J, Miller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146-156.
129
Tropea D, Caleo M, Maffei L (2003) Synergistic effects of brain-derived neurotrophic factor
and chondroitinase ABC on retinal fiber sprouting after denervation of the superior
colliculus in adult rats. J Neurosci 23:7034-7044.
Weaver LC, Marsh DR, Gris D, Brown A, Dekaban GA (2006) Autonomic dysreflexia after
spinal cord injury: central mechanisms and strategies for prevention. Prog Brain Res
152:245-263.
Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science
288:1765-1769.
130
CHAPTER 6
Our delivery method of chABC provides an alternative treatment to spinal cord injury.
The results showed enhanced axonal sprouting around the lesion site and improved
strategies to promote axonal regrowth through the lesion site to regain functional pathways,
and apply this method for clinical treatment. In this study no axon enters the lesion site and
complete functional recovery was not achieved yet. Therefore, further studies will be
treatment. There are several factors that need to be investigated and determined in order to
design the optimized chABC administration: 1) characterize release profile of chABC with
For example, with our delivery method the chABC activity was limited to 1 mm
away from lesion site and it is not clear whether the area is a large enough to induce axonal
sprouting and functional improvement in clinical study. Because chABC is a relatively large
molecule, diffusion through neural tissue and extracellular space is limited. chABC delivered
via the hydrogel-microtube system has advantages and diffuses deeper into the tissue (up to
131
1mm) compared to intrathecal delivery of chABC. However in humans, there might be a
need for greater diffusion distances as the CSPG deposition zone may be deeper and larger,
but whether or not chABC diffusion into injured human cord will be a limitation remains to
In this study, single injection of chABC and sustained delivery of chABC did not
increase inflammatory response compared to other controls (no treatment and P‟ase delivery)
after injury. However the effects of chABC on nerve tissue and immune system need to be
considered. When chABC was delivered intrathecally to intact spinal cord, robust sprouting
of descending projects and primary afferents were observed (Barritt et al., 2006). However,
in that study, it did not lead an increase in mechanical allodynia (noxious response to a
Other studies also reported that intrathecal delivery of chABC (0.2 ~ 1 ml of 200 U/ml)
showed any morphologic changes in the spinal cord and any neurophysiologic changes in
tibial nerves in rabbits (Olmarker et al., 1991). No adverse effects on nerve tissue and blood
vessels were observed after intrathecal delivery in pig except a slight intrathecal fibrotic
reaction (Olmarker et al., 1996). In those studies, they expected that approximately 1/40
response. In this study, chABC was delivery locally at the lesion site with lipid microtube
132
and hydrogel, however antigenicity and immunogenicity of chABC and the delivery system
still need to be tested. The safety test of chABC for side effects on nerve tissues and immune
response needs to be investigated with the relevant dosage range for clinical application and
duration of release agents. To prolong the period of sustained delivery, longer lipid
microtubes can be considered as a delivery vehicle in vivo. The length and properties of
solution and changing ratio between ethanol and water for the solution to dissolve lipid
(Lando et al., 1990; Thomas et al., 1995; Meilander et al., 2001). With the original protocol,
average 37 micron length of microtube is fabricated. The adjustments were made to the
original protocol. 70% ethanol and 1 mg lipid per 1 ml ethanol solution were fixed and a part
of cooling process modified; the rate of decreasing temperature (53-23 deg) changed from
1deg/40min to 1 deg/10 min. The measured average length of microtube was approximately
100 micron (Fig. 6.1). We demonstrated that the length of microtube is controllable and since
the release profile of loaded agents is dependent on the length of microtube, it facilitates to
control drug delivery. The release duration and rate of agent from the delivery scaffold also
can be controlled by modifying the gel. The release profiles are dependent on the type and
133
50
40
Number of microtubes
30
20
10
0
~40 40-60 60-80 80-100 100-120 120-140 140-160 160-180 180-200 200~
chABC and NT-3 was delivered to examine the effect on levels of CSPG deposition, axonal
regeneration and functional recovery after SCI in rats. We demonstrated that there are
significant differences in CSPG digestion, axonal sprouting and functional recovery between
single injection and sustained delivery. Some other studies reported that there is no
significant difference in sprouting axons between chABC treatment and untreated groups
after SCI (Iaci et al., 2007). This implicates that the amount/concentration of delivered
chABC and delivery frequency/period are important to elicit relevant axonal regeneration
134
and behavioral recovery. Therefore, it is necessary to conduct experiments to optimize the
concentration and total amount, and delivery period. The optimal dosage delivered in
combination of chABC and NT-3 also needs to be determined, because combining each
optimal dosage for individual delivery of chABC or NT-3 might not be the best possible
dosage for the combination therapy. For example, other study showed that dramatically
improved (~40 times) axonal sprouting was observed with combination therapy of chABC
and NT-3 (Massey et al., 2008). In this long term in vivo study, even more enhanced axonal
sprouting and functional recovery were observed in chABC/NT-3 treated animals than
individually treated animals. If the concentration and ratio between chABC and NT-3 are
To evaluate the effects of chABC two animal studies were conducted; a 2 week
Chapter 5. The duration of the in vivo study is a critical factor to determine whether the
administrated therapy is effective or not to treat injuries or diseases. For example, in this
study if we had terminated earlier than 6 weeks, we would not observe the significantly
improved functional recovery in locomotion assessed by stride length between animal groups.
Similarly, if we conduct longer period animal study, such as 8 or 12 weeks, more fibers
might outgrow closer to the lesion and even completely grow through/around the lesion site
locomotion controls.
135
6.6 RATE AND AMOUNT OF CSPG DEPOSITION IN VIVO AFTER SCI
In the in vivo study, significant differences were observed in the CS-56-IR and 3B3-
microtube treated groups and controls. These results suggested that the enzyme, chABC, still
retains its enzymatic activity after being released from the hydrogel-microtube delivery
scaffold in vivo, and digests CSPGs more effectively than the controls, chABC-hydrogel or
chABC-single injection treated groups. However, it is not clear how constant the enzymatic
activity of released chABC remains over this time period and how much chABC is released
from the delivery scaffold and diffused into the tissue. Once chABC is released from the
hydrogel-microtube delivery scaffold, it can be assumed that the activity of chABC will be
similar to fresh, unstabilized chABC, because the ratio of trehalose to chABC becomes a lot
diluted. It is shown that the production of several CSPGs is differentially regulated following
spinal cord injury (Jones et al., 2003) by immunohistological analysis. However, the rates
and amount of CSPG deposition are not known and depend on injury models, degree of
injury and age (Gilbert et al., 2005). Therefore, it would be clinically desirable if the CSPG
deposition rate can be determined for specific injury models and degree of injury.
This study showed that combination therapy with thermostabilized chABC and NT-3
delivery system with thermostabilized chABC could provide permissive environment for
neurite outgrowth and can be combined with other strategies, such as delivery of
neurotrophic factor, cell transplantation (NSC, olfactory, Schwann cell, autologus peripheral
136
nerve graft, etc), and acellular scaffold implantation. This combination therapy can be a
potent treatment for many neurodegenerative diseases by promoting axonal regeneration and
restoring complete functional recovery after neuronal injuries. One cell transplantation
strategy, neural stem cell (NSC) therapy, is very promising; however, this approach needs to
Factors regulating NSC have been investigated, and studies showed that the
provided that CSPGs regulate neural stem/progenitor cell proliferation and intervene in fate
decision making between the neuronal and glial lineage. In vitro experiments showed that
CSPGs inhibit migration of neural stem/progenitor cell (NSPC)-derived cells and chABC
treatment attenuated the inhibitory effect (Ikegami et al., 2005; chABC). Also, cell-surface
soluble GAGs involve in internalization of extracellular proteins for some progenitor cell to
stem cells (Ueda et al., 2008; heparin). As explained above, chABC can be used to modify
the local environment in CNS via digesting CS-GAGs and also to selectively degrade GAGs
The use of NSCs in conjunction with chABC may prove to be therapeutic in repairing
CNS by modulating cellular matrix and CSPGs, which act as a barrier for stem cell migration
after transplantation. In many cases, however, transplanted stem cells fail to migrate and
integrate into the host tissue and CSPGs are considered as a putative inhibitor of stem cell
migration in vivo. chABC treatment combined with NSPC transplantation into injured spinal
cord promoted migration of the transplanted cell into the host spinal cord and resulted in
137
(Ikegami et al., 2005; chABC). When Müller stem cells were implanted with chABC into
degenerating retina , this resulted in dramatic increase of migration of stem cell into all of
the retina cell layers (Singhal et al., 2008; CSPGs; Fawcett) and differentiation into retinal
Studies suggest that chABC treatment can facilitate migration and differentiation of
be a promising strategy for the regeneration of injured or degenerated CNS tissues. Also, our
chABC treatment can be combined with delivery of other neurotrophic factors and cell
transplantations.
It is hard to simulate the human cases of SCI in animal experiments: first, human SCI
occurs in the closed vertebral system generally under conscious state and a combination force
of flexion, extension, rotation and compression works on the cord when the injury happens
(Sharma et al., 1993; Choi, 1996). Most human SCI results from fracture of vertebral column
conducted on the posterior side of the cord with laminectomy (opened vertebra system) under
anaesthetized state and one force, such as contusion, compression or incision, is applied to
produce injury for high reproducibility (Sharma, 2005a). Therefore, human SCI cases are
more complex and only few cases are similar to experimental models in terms of the
magnitude and severity of the injury (Sharma, 2005b; Onifer et al., 2007). Table 3
138
Parameters Human Rat
Number of neurons 109 0.36
Length (cm) 43-45 8-10
Weight (g) 34 0.7
Proportion to brain
2 35
(volume %)
Glial/neuron ratio 12-16 10-14
2438 50*
Weight drop injury (g) 971 20*
485 10*
Our study required an SCI model allowing for behavioral and immunohistological
analysis to examine functional recovery and axonal regeneration. There are several
commonly used models for spinal cord injury and each has advantages and disadvantages:
complete spinal transection, dorsal over hemisection, lateral hemisection injury, compression
and contusion.
The complete transection model removes any overlap between spared and regenerated
fibers. However, the animal undergoes severe pain and various syndromes, such as bowel
and bladder dysfunction and no functional recovery with hindlimbs, because the transection
completely eliminates functions below the injury site. Therefore, it requires relatively long
term management with various post-surgical complications and morbidity is higher than
The contusion model could be the most clinically relevant model, although it still
lacks some of the absent factors described above. A fluid filled cyst forms at the impacted
area and is surrounded by tissue containing spared/intact axons (Kwon et al., 2002). Because
139
of the spared axons around the cyst, it is hard to distinguish between spared and regenerated
axons (Steward et al., 2003) and it is a limitation for studies focusing on regeneration.
The lateral transection model is a complete transection of one side of the spinal cord.
In this model all pathways in one side of the cord are severed. However, intact axons in the
non-lesioned side can sprout into the lesioned side and make it hard to distinguish from
The dorsal over hemisection model has relatively moderate severity of injury. In this
injury model, damage is limited in the dorsal column and animals undergo less stress and
pain with less post-surgery dysfunctions than other injury models. Axonal regeneration can
be easily quantified by injection of anterograde tracer (i.e. BDA) to the corticospinal tract
(CST) or retrograde tracer to the primary sensory pathway (i.e. cholera toxin subunit B), and
spared fiber is not a critical issue. Therefore, the dorsal over hemisection model was chosen
for our study. There is a chance of spared fibers in the bilateral transected CST (Vavrek et al.,
2006), and the primary sensory pathway was chosen in this study to examine regenerating
axons.
As a further study, contusion injury model can be used to examine the delivery
efficiency of our topical delivery method with chABC and develop a more relevant delivery
method for human therapy. In the contusion model, it would be difficult to deliver drugs deep
through the surrounding tissue to the cyst with our topical delivery model if the drug is not
small enough. Diffusion efficiency of chABC needs to be examined in this model. If the
diffusion is not enough to remove CSPGs and promote axonal outgrowth, alternative delivery
140
6.9 REFERENCES
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ
(2006) Chondroitinase ABC promotes sprouting of intact and injured spinal systems
after spinal cord injury. J Neurosci 26:10856-10867.
Bull ND, Limb GA, Martin KR (2008) Human Muller stem cell (MIO-M1) transplantation in
a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol
Vis Sci 49:3449-3456.
Gilbert RJ, McKeon RJ, Darr A, Calabro A, Hascall VC, Bellamkonda RV (2005) CS-4,6 is
differentially upregulated in glial scar and is a potent inhibitor of neurite extension.
Mol Cell Neurosci 29:545-558.
Iaci JF, Vecchione AM, Zimber MP, Caggiano AO (2007) Chondroitin sulfate proteoglycans
in spinal cord contusion injury and the effects of chondroitinase treatment. J
Neurotrauma 24:1743-1759.
Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans
neurocan, brevican, phosphacan, and versican are differentially regulated following
spinal cord injury. Exp Neurol 182:399-411.
Kwon BK, Oxland TR, Tetzlaff W (2002) Animal models used in spinal cord regeneration
research. Spine (Phila Pa 1976) 27:1504-1510.
Lando JB, Hansen JE, Sudiwala RV, Rickert SE (1990) The formation of polymerizable
tubules. Polym Adv Technol 1:27-32.
Massey JM, Amps J, Viapiano MS, Matthews RT, Wagoner MR, Whitaker CM, Alilain W,
Yonkof AL, Khalyfa A, Cooper NG, Silver J, Onifer SM (2008) Increased
chondroitin sulfate proteoglycan expression in denervated brainstem targets following
spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase
ABC and neurotrophin-3. Exp Neurol 209:426-445.
141
Meilander NJ, Yu X, Ziats NP, Bellamkonda RV (2001) Lipid-based microtubular drug
delivery vehicles. J Control Release 71:141-152.
Meilander NJ, Pasumarthy MK, Kowalczyk TH, Cooper MJ, Bellamkonda RV (2003)
Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J
Control Release 88:321-331.
Onifer SM, Rabchevsky AG, Scheff SW (2007) Rat models of traumatic spinal cord injury to
assess motor recovery. ILAR J 48:385-395.
Singhal S, Lawrence JM, Bhatia B, Ellis JS, Kwan AS, Macneil A, Luthert PJ, Fawcett JW,
Perez MT, Khaw PT, Limb GA (2008) Chondroitin sulfate proteoglycans and
microglia prevent migration and integration of grafted Muller stem cells into
degenerating retina. Stem Cells 26:1074-1082.
Thomas BN, Safinya CR, Plano RJ, Clark NA (1995) Lipid Tubule Self-Assembly: Length
Dependence on Cooling Rate Through a First-Order Phase Transition. Science
267:1635-1638.
142
Trounson A (2009) New perspectives in human stem cell therapeutic research. BMC Med
7:29.
Vavrek R, Girgis J, Tetzlaff W, Hiebert GW, Fouad K (2006) BDNF promotes connections
of corticospinal neurons onto spared descending interneurons in spinal cord injured
rats. Brain 129:1534-1545.
143